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Tuberculosis (TB) remains a major public health concern.  The BCG vaccine 
is, currently, the only vaccine against TB and, although it provides some 
protection against disseminated forms of TB, its effectiveness in preventing 
primary infection and disease progression to pulmonary TB is highly varied. 
A number of potential new TB vaccine candidates have been identified and 
are, currently, undergoing clinical trials.  One such candidate is MVA85A. 
This study aims to assess the potential cost-effectiveness of a new TB
vaccine, the MVA85A vaccine. The study compares two TB vaccine
strategies, from the perspective of the South African Government:
i. BCG, given at birth, which is the current standard of care in South
Africa; and
ii BCG, given at birth, together with a booster vaccine (MVA85A)
given at 4 months, which is the potential new strategy.
The study employs Decision Analytical Modelling, through the use of a
Markov model, to estimate the costs and outcomes of the two strategies.
The cumulative costs and outcomes of each intervention are used to
calculate the cost-effectiveness ratio (CER) (i.e. the cost per TB case averted
and the cost per TB death averted) for each intervention. These two cost-
effectiveness ratios are compared using an incremental cost-effectiveness 
ratio (ICER), which represents the additional cost per additional benefit
received.
The results of the cost-effectiveness analysis indicate that the MVA85A 
strategy is both more costly and more effective – there are fewer TB cases 
and deaths from TB – than BCG alone.  The Government would need to 
spend an additional USD 1,105 for every additional TB case averted and 











Given the disappointing results of the MVA85A vaccine clinical trial – 
showing an efficacy of only 17.3%, this study will predominantly contribute to 
establishing an efficacy threshold for future vaccines. 
Our research also contributes to the body of knowledge on economic 
evaluations involving new TB vaccines as – to the best of our knowledge – 
this is the first cost-effectiveness analysis conducted using trial data involving 
a novel TB vaccine and providing a direct comparison with BCG vaccination. 
Furthermore, it provides a standardized Markov model, which is relatively 
simple to adapt to local settings and, which could be used in the future, to 
estimate the potential cost-effectiveness of new TB vaccines in children 
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1.1. Problem statement 
Global Epidemiology of TB 
Globally, it is estimated that, in 2010, there were 8.8 million new cases 
and 12 million prevalent cases of tuberculosis (TB) and 1.45 million 
deaths associated with TB.  Furthermore, 2 billion – or a third of the 
world’s population – is believed to be latently infected with TB (World 
Health Organization 2012). 
Although Asia had the highest number of new cases – 59% compared 
to Africa at 26% – Africa still has the highest proportion of cases per 
population – 276/100,000 compared to 193/100,000 in Asia and 
128/100,000 globally.  Africa also accounts for 82% of all TB cases 
amongst people living with HIV (World Health Organization 2012). 
Since 2000, 22 countries have been identified as “high-burden 
countries” and have been prioritised globally.  These 22 countries 
account for approximately 80% of TB cases worldwide.  South Africa is 
included in the 22 countries and, in 2010, was one of five countries with 
the highest number of incident cases; the others being China, India, 
Pakistan, and Indonesia.  South Africa is the only country, of the 22, 
showing an increase in the incidence rate (World Health Organization 
2012). 
The numbers affecting children are not readily available and tend to be 
unreliable for a variety of reasons, including the difficulties in diagnosing 
TB in children and the lack of standardised data collection.  The latest 
estimates are that 520,000 (490,000 – 550,000) new cases and 64,000 
(58,000 – 71,000) deaths occurred in children in 2010 (Sismanidis 
2012).  This represents 6% of new cases globally; although previous 
estimates were around 10% (Marais, Gie et al. 2006).  The World 
Health Organization is in the process of preparing new estimates that 















The Millennium Declaration in 2000 established the 8 Millennium 
Development Goals (MDGs) to be achieved by 2015, which included 
targets for TB control. 
– MDG target 6.C: Have halted by 2015 and begun to reverse the 
incidence of malaria and other major diseases 
 Indicator 6.4 Incidence, prevalence and death rates associated 
with tuberculosis 
 Indicator 6.5 Proportion of tuberculosis cases detected and 
cured under directly observed treatment short course 
The Global Partnership to STOP TB (STOP TB Partnership), founded in 
2001 and hosted by the World Health Organization, brings together 
various stakeholders (e.g. technical agencies, government, 
Indicators
Data/Date 
Range Type of Data World South Africa
Tuberculosis HBCs 2011 Text 22 Yes
New TB Cases 2010 # 8,800,000 490,000
New TB Smear Positive Cases 2008 # 4,300,000 200,000
New TB Case Rate 2010 Rate per 100,000 128 981
People living with TB 2010 # 12,000,000 400,000
TB Prevalence Rate 2010 Rate per 100,000 178 795
TB Smear Positive Case Rate 2008 Rate per 100,000 64 410
TB Deaths 2010 # 1,100,000 25,000
TB Death Rate 2010 Rate per 100,000 15 50
TB Incidence in HIV  People 2010 # 1,100,000 300,000
TB Incidence in HIV  People per 
100,000 Population 2010 Rate per 100,000 16 591
HIV Prevalence in Incident TB Cases 2010 % 23.00% 60.00%
TB Prevalence in HIV  People 2007 # 687,024 167,799
TB Prevalence in HIV  People per 
100,000 Population 2007 Rate per 100,000 10 345
TB Mortality in HIV  People 2007 # 456,218 93,702
TB Mortality in HIV  People per 100,000 
Population 2007 Rate per 100,000 7 193
DOTS Coverage 2007 % 94% 100%
DOTS Detection Rate 2007 % 63% 78%
DOTS Treatment Success 2006 % 85% 74%
Population 2011 # 6,928,198,253 49,004,031
Population Under Age 15 2011 % 27% 30%
Death Rate (overall) 2011 Rate per 1,000 8.12 17.09
Infant Mortality Rate 2011 Rate per 1,000 41.61 43.2
Under-Five Mortality Rate 2010 Rate per 1,000 57 57
GDP Per Capita 2010 $ $11,125 $10,565











nongovernmental organizations (NGOs), academia, and the private 
sector) in support of the fight against TB. 
– The STOP TB Partnership has endorsed the following targets linked 
to the MDGs. 
 by 2015: reduce prevalence and deaths due to TB by 50% 
compared with a baseline of 1990 
 by 2050: eliminate TB as a public health problem 
Global Efforts to develop a new TB vaccine 
In the mid-2000’s, modelling studies showed that existing strategies 
alone would not be sufficient to achieve the 2050 target of elimination of 
TB as a public health concern.  It was recognized that new strategies 
for prevention (e.g. new tools for diagnosis and a new vaccine) and 
treatment (e.g. shorter, more effective regimens) would be needed 
(Dye, Garnett et al. 1998, Abu-Raddad, Sabatelli et al. 2009).  
Particularly, it was acknowledged that new vaccines that both prevented 
infection (pre-exposure) and disease (post-exposure) progression are 
needed (Young, Dye 2006). 
Following the successful sequencing of the Mycobacterium 
Tuberculosis (M.tuberculosis) genome as well as progress in 
sequencing bacille Calmette–Guérin (BCG), a number of potential new 
TB vacci e candidates have been identified and are currently in clinical 
trials.  One such candidate is MVA85A. 
1.2. Literature Review 
BCG Vaccine 
The BCG vaccine was first used in humans in 1921 and was included in 
the World Health Organization’s Expanded Programme of Immunization 
(EPI) schedule in 1974 (Kaufmann, Hussey et al. 2010).  The BCG 
vaccine is, currently, the only vaccine against tuberculosis.  Data on its 











pulmonary TB is highly varied – ranging from 0–80% (Brewer 2000, 
Colditz, Berkey et al. 1995, Colditz, Brewer et al. 1994, Fine 1995, 
Rodrigues, Diwan et al. 1993).  However, there is a general consensus 
that BCG is protective against disseminated forms of TB, including 
military and meningeal TB (Brewer 2000, Colditz, Berkey et al. 1995, 
Colditz, Brewer et al. 1994, Fine 1995, Rodrigues, Diwan et al. 1993).  
Data on the duration of protective effect is also mixed, but it appears 
that it is limited to approximately 10 years (Sterne, Rodrigues et al. 
1998). 
Revaccination with BCG does not enhance its effectiveness or extend is 
duration of protectiveness (Rodrigues, Pereira et al. 2005). 
The World Health Organization recommends the immunization of all 
infants in high TB burden countries, except those known to have a 
compromised immune system (e.g. HIV), with the BCG vaccine. 
South Africa: BCG vaccination coverage 
South Africa introduced universal BCG vaccination for all infants at birth 
in 1972 (van Rie, Beyers et al. 1999).  According to the Department of 
Health’s 2010/2011 Annual Report, 89.4% of children less than one-
year old are fully immunized (Department of Health 2011).  Given that 
children under one receive a number of vaccinations over a period of 
0–9 months, it is possible that BCG coverage is higher.  A study 
conducted in the Western Cape Province, showed a coverage rate of 
99% (Corrigall, Coetzee et al. 2008). 
MVA85A 
MVA85A is a “post-exposure” sub-unit vaccine that is designed to boost 
the immunological response of BCG.  MVA stands for “modified 
vaccinia Ankara”, which is the delivery system used to present the 
mycobacterial antigen 85A to the immune system.  It has undergone a 
number of Phase I and Phase II Clinical Studies which has shown that it 
is well tolerated, has no significant safety concerns, is highly 











antigen 85A in people who have previously been vaccinated with BCG 
(McShane 2011, Odutola, Owolabi et al. 2012, Scriba, Tameris et al. 
2011). 
MVA85A is, currently, being tested in a Phase IIb Clinical Trial in HIV-
negative Children in Worcester, Western Cape, South Africa. 
Cost-Effectiveness Analysis 
A Cost-Effectiveness Analysis (CEA) is one of four types of economic 
evaluation in which health outcomes are expressed in natural units 
(e.g. patients cured, infections avoided, lives saved) and the results as 
the “cost per unit of outcome”.  A CEA addresses questions of technical 
efficiency as it compares alternative ways of achieving the same 
objective.  CEA is an appropriate framework to compare two 
interventions where one is the current standard of care and the other is 
a new intervention, as it provides information on the relative value 
provided by the “innovation” (Walley, Haycox et al. 2004). 
Decision analytic modelling may be used to generate the costs and 
health outcomes for a CEA as it provides a structure in which evidence 
from a variety of sources can be incorporated; allows for the 
extrapolation of data beyond the trial follow-up period; and allows for 
the inclusion and management of uncertainty (Drummond 2005).  In this 
study, Markov modelling is applicable as TB is a chronic infectious 
disease which has a number of possible and recurring health states. 
Cost-Effectiveness of BCG vaccination 
“Immunization remains one of the most cost-effective health 
interventions, even with newer, more expensive vaccines” (World 
Health Organization, UNICEF et al. 2009). 
Despite the controversies on the effectiveness of BCG and its role in TB 
control, a cost-effectiveness analysis of the effect of BCG vaccination 
on TB meningitis and miliary TB, conducted in 2006, declared it to be 











economic evaluations involving vaccination against TB, including 
potential new vaccines, also concluded that universal BCG vaccination, 
in developing countries with a high burden of TB, is cost effective (Tu, 
Vu et al. 2012). 
Cost-Effectiveness of MVA85A vaccination 
Although presentations pertaining to market studies and a cost-
effectiveness study were identified, no studies evaluating the cost-
effectiveness of MVA85A have been identified in the published 
literature. 
1.3. Rationale and justification for research 
Resources are scarce and governments, as well as international 
financing organizations (e.g. the Global Fund, GAVI Alliance), need to 
make informed decisions about where best to allocate resources in 
order to maximize population health benefits. 
A number of new vaccines (e.g. pneumococcal, rotavirus, and human 
papillomavirus) have been developed over the past decade which 
increases the competition for these limited resources in developing 
countries (Kim, Goldie 2008). 
This work will contribute to global discussions on the development of 
new TB vaccines and, specifically, will add to the Oxford-Emergent 
Tuberculosis Consortium’s (OETC) body of knowledge when deciding 
whether or not to take forward the development of MVA85A. 
If MVA85A is formulated into a “finished pharmaceutical product”, this 
study could help to establish the launch price of MVA85A in South 
Africa and, possibly, other developing countries. 
Furthermore, specifically in South Africa, the study will contribute to the 
policy discussion on whether or not to incorporate MVA85A into the EPI 











and simplified manner, on the relative value of MVA85A vaccination for 
the prevention of TB disease in children. 
1.4. Research aim and objectives 
Overall aim 
To examine the potential cost-effectiveness of adding the MVA85A 
vaccine to the BCG vaccine in HIV negative children from the 
perspective of the South African Government. 
Specific objectives 
(a) To develop a Markov state transition model that simulates the 
natural history of tuberculosis infection and disease in general and, 
where appropriate, in the South African context. 
(b) To estimate the economic and health outcomes, over a 10-year 
period of two vaccination strategies aimed at reducing the incidence 
and mortality of tuberculosis disease.  The two strategies are: 
– BCG at birth 
– BCG at birth plus a booster vaccine (MVA85A) at 4–6 months 
(c) To estimate the incremental cost effectiveness ratio of adding a 
booster vaccine (MVA85A) to BCG in terms of cost per TB case averted 
and per TB death averted. 
2. Methodology 
Overview 
This study is Cost-Effectiveness Analysis (CEA) employing Markov 
modelling, using the TreeAge Pro Suite® 2012 software.  The model 
will follow the natural history of tuberculosis (TB) disease in children. 
The study will be conducted from the perspective of the South African 











charge to all health-care institutions (Loots, personal communication 
2012, July 6; Johnson and Arnot, personal communication 2012, July 13). 
Description of alternatives 
The study examines the potential cost-effectiveness of adding a new TB 
booster vaccine – MVA85A – to the current BCG vaccine. 
The two alternatives being compared are: 
– the current standard of care, which is vaccinating all those who 
are HIV-negative; and 
– the current standard of care plus a booster vaccine given at 
4–6 months. 
2.1. Decision model 
Model structure 
The proposed structure draws on structures used in other studies on 
tuberculosis control and prevention strategies, which employed decision 
analysis (Clark, Cameron 2006, Mandalakas, Hesseling et al. 2013, 
Tseng, Oxlade et al. 2011). 
This model will be a static, deterministic, population-based, closed, and 
discrete model. 
The costs and consequences/outcomes of the two strategies will be 
compared.  The costs and consequences will be estimated through 
modelling the vaccination of a hypothetical cohort of HIV-negative 
newborns and following them from birth through to 10 years of age.  A 
time horizon of 10 years was chosen as this represents the time period 
over which there is a unique pathway of TB in children.  Beyond 10 
years, the course of TB tends to mimic that of adults.  To extend the 
time horizon beyond 10 years would require having two model 












Modelling is employed to extend the costs and consequences/outcomes 
of the two interventions beyond the trial time-horizon of 2 years. 
Six-month cycles will be employed as this period is associated with 
treatment of both active and latent TB.  The model will run for 10 years, 
following the natural history of TB, the duration of effectiveness of BCG, 
and to allow for all relevant differences in future costs and 
consequences to accrue for the two interventions. 
Consistent with recommendations and published studies, all future 
costs and consequences will be discounted at 3% (Weinstein, Siegel 
et al. 1996). 
Herd immunity is not considered in this model as humans have a 
natural immunity to infection with M.tuberculosis, which is not further 
enhanced by BCG and, at this time, is not being studied for MVA85A. 
Health states 
The Markov model will follow the natural history of tuberculosis (TB) 
disease in children.  The disease is classified into mutually exclusive 
health states, which represent the clinically and economically significant 
events of the disease. 
The states are mutually exclusive as patients can only be in one health 
state at any given time.  Transition between states is permitted 
according to specific transition probabilities and specific criteria.  
Patients may remain in certain health states (e.g. uninfected).  “Death” 
is considered to be an absorbing state i.e. once a patient has entered it, 
the patient cannot leave.  This model assumes that once a patient is 
infected with TB, the patient can never be “uninfected”, again.  All 
patients will start out in the “uninfected” health state.  The following 














– Pulmonary TB (PTB) 
– Miliary TB (mTB) 
– TB Meningitis (TBM) 
– Death from TB 
– Death from other causes 
Health states and possible transition between states 
Health state Possible transitions 
Uninfected Remain uninfected, become infected, or die from 
causes unrelated to TB 
Infected Remain infected, become reinfected, progress to one of 
the three TB disease states, or die from causes 
unrelated to TB 
Reinfected Go back to being infected, progress to one of the three 
TB disease states, or die from causes unrelated to TB 
Pulmonary TB 
(PTB) 
Go back to being infected, become reinfected, die from 
TB, or die from causes unrelated to TB 
Miliary TB (mTB) Go back to being infected, become reinfected, die from 
TB, or die from causes unrelated to TB 
TB Meningitis 
(TBM) 
Go back to being infected, become reinfected, die from 
TB, or die from causes unrelated to TB 
Death (all cause) Remain dead (absorbing state) 
Death (TB-related) Remain dead (absorbing state) 
Refer to Annex 1 for a graphical representation of the health states and the 
possible transitions amongst them. 












Effectiveness will be expressed as TB cases averted and TB deaths 
averted.  In order to generate these, the model will be populated with 
parameters relevant to the natural course of the disease and which 
reflect the probability of moving between various health states. 
Age-specific risks for progression to three different TB disease states – 
pulmonary TB (PTB), miliary TB (mTB), and TB meningitis (TBM) – and 
the risk of death from these disease states will be reflected in the model 
together with the risk of TB infection.  These data will be taken from the 
published literature, expert opinion, and government data bases such 
as the South African electronic TB register. 
Data on all-cause mortality rates were taken from WHO 2009 Life-
Tables and were adjusted to remove the age-specific risk of dying from 
one of three TB disease states. 
Data on the efficacy of MVA85A vaccine will be taken from the Phase 
IIb Clinical Trial currently underway in Worcester, Western Cape, 
South Africa.  The trial database closes on 31 December 2012 and data 
will be made available for this study within the first quarter  of 2013.  
This trial received its ethics approval from the UCT Ethics Committee 
on 17 December 2008 (REC REF 291/2008). 
Assumptions on up-take or coverage rates for MVA85A will be obtained 
through consultation with experts.  No decision on whether or not to 
include adverse effects has yet been made.  Given that studies to-date 
have not shown any significant side effects, it is likely that these will be 
excluded  
Cost data 
Costs are the value of resources used to achieve a particular outcome.  
They are calculated by identifying all the relevant inputs, determining 
“quantity” of each input, and the unit cost of each input.  Which costs 
are included in a CEA depend on the perspective taken.  As this study 











costs to the South African Government which are associated with 
providing the vaccine and treating TB disease will be considered. 
This data will be obtained from published and unpublished studies as 
well as directly from the Department of Health.  Emergent will provide 
information on the potential cost of the MVA85A vaccine.  Costs will be 
represented in 2012 US dollars. 
Proposed parameters 
Type Parameter Source 
Demographic Age-specific mortality 
rates 
The World Health 
Organization’s Life-Tables 
Epidemiological Annual risk of infection 
(ARI) 
Published literature (local 
studies); expert opinion 
Natural history Age specific: 
Risk of disease progress 
– pulmonary & 
disseminated TB; 




e-TB register; StatsSA mortality 
data 
Vaccine Drop-out rate DTP3 and 
MCV; duration of 
protective effect 
Published literature 
Cost Vaccine, TB treatment Published and unpublished 
literature; tender awards; 
personal communication 
Economic Discount rate Published literature 













The health outcomes that will be measured are TB cases averted and 
TB deaths averted.  Given that very limited information is available on 
the utilities associated with the various health states for TB in children, 
as well as the difficulty in determining these, the Quality-Adjusted Life-
Year (QALY) will not be used. 
Economic outcomes 
The cost per TB case averted and the cost per TB death averted will be 
estimated from the Markov model for each intervention. 
According to the World Health Organization’s Choosing Interventions 
that are Cost-Effective (CHOICE) project, interventions are considered 
to be highly cost-effective at less than GDP (Gross Domestic Product) 
per capita, cost-effective at 1–3 times GDP per capita, and not cost-
effective at more than 3 times GDP per capita (World Health 
Organization CHOICE 2012). 
An incremental cost-effectiveness ratio (ICER) will also be calculated.  
This ratio represents the additional cost per additional unit of effect. 
2.4. Model validation 
Once constructed, the model will be validated through consultation with 
experts in paediatric TB, TB vaccine development, and economic 
evaluation. 
2.5. Sensitivity analysis 
Sensitivity analysis involves varying the value of parameters that are 
important and, possibly, uncertain over a plausible range to determine 
the impact on the cost-effectiveness ratios (Walley, Haycox et al. 2004). 
Our study will employ one-way sensitivity analysis wherein the value of 











A threshold analysis for efficacy will also be done. 
3. Work plan and logistics 
This study will be carried out over a period of 12 months.  The results 
form part of a dissertation for a Master of Public Health in Health 
Economics that is planned for submission in August 2013. 
4. Budget 
This study is self-funded and forms part of a dissertation for a Master of 
Public Health in Health Economics. 
5. Ethical considerations 
Ethics approval will be obtained from the University of Cape Town 
Ethics Committee.  However, as this study does not involve human 
subjects, no major ethical c nflicts are anticipated. 
Data used to populate the model will be taken from published literature 
and, where necessary, expert opinion.  Data on the efficacy of the 
MVA85A vaccine will be sourced from the Phase IIb Clinical Trial, which 
received its ethics approval from the UCT Ethics Committee on 
17 December 2008 (REC REF 291/2008). 
6. Dissemination of study findings 
The results of this study form part of a dissertation for a Master of 
Public Health in Health Economics. 
It is hoped that this study will be published in a journal and the policy 











In addition, the findings will be shared with OETC, who are developing 
MVA85A for the global market, and the Western Cape Department of 
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Parameters Value Range References 
Risk of death from pulmonary TB (%) 
< 3 years 0.74952 
3-5 years 0.09120 
> 6 years 0.58766 • Electronic databases (Provincial Government Western Cape 
Risk of death from miliary TB (%) Department of Health 2012, Statistics South Africa 2012b) • Calculated using average for 2005-2009 and e-TB data 
< 3 years 23.52941 • Expert opinion 1 
3-5 years 9.09091 
> 6 years 16.66667 
Risk of death from TB meningitis (%) 
< 3 years 25.00000 
3-5 years 26.66667 
> 6 years 20.00000 
MVA85A efficacy against TB disease (%) 17.3 12.3 - 22.3 • Published literature (Tameris, Hatherill et al. 2013) 
Up-take BCG (%) 99.0 99.0 - 99.5 • Published literature (Department of Health: Republic of South Africa 2011, Corrigall , Coetzee et al. 2008) 
Up-take MVA85A 85.0 76.4 - 89.5 • Calculated 
• Published literature and electronic database (Saloojeei , 
Drop-out rate DTP3 to MCV 14.0 9.5 - 23.1 Bamfordii 2006, Health Systems Trust 2007) 
• Expert Opinion 1 
• Published and unpublished literature (Mandalakas, Hesseling et 
Cost of BCG vaccination (USD 2012) 13.57 13.43 - 14.28 al. 2013) 
• Personal Communication (Amot, Hayes 2012) 
• Personal Communication Oxford Emergent Tuberculosis 
Cost of MVA85A vaccination (USD 2012) 28.22 20.22 - 48.22 Consortium (OETC) • Published and unpublished literature (Mandalakas, Hesseling et 
al. 2013) 
1 Expert opinion provided by: Professor Willem Hanekom , Dr Mark Hatherill, Professor Anneke Hesseling, Dr Helen McShane, Dr Hassan Mohammed, 













Parameters Value Range References 
Costs of diagnosis and treatment PTB 
(USD 2012) 
0-2 years 406.13 
3-5 vears 433.13 
6-10 years 459.29 
Costs of diagnosis and treatment mTB 
(USD 2012) 
0-2 years 3,184.76 
• Personal Communication (Arnot , Hayes 2012, von Zeil 2012) 
3-5 years 3,213.57 • Published and unpublished literature (Mandalakas, Hesseling et 
6-10 years 3,241.54 
al. 2013) 
Costs of diagnosis and treatment TBM • Published report (Statistics South Africa 2012a) 
(USD 2012) 
0-2 vears 29,782.98 
3-5 years 29,844.60 
6-10 years 29,881 .88 
Discount rate outcomes (%) 3 0 6 • Published literature (Weinstein, Siegel et al. 1996, Severens, 
Discount rate_costs (%) 3 0-6 
Milne 2004, Torgerson, Raftery 1999, Langer, Holle et al. 2012, 
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This study employs Decision Analytic Modelling, through the use of a Markov 
model, to estimate the potential Cost-Effectiveness of a new TB vaccine, 
which is still under development.  As such, the objectives of the literature 
review were to identify information on: 
– tuberculosis (TB), as a public health concern, and its global impact; 
– the natural course of tuberculosis (TB) in children, including the 
childhood-specific risks associated with acquiring TB infection, 
developing TB disease, and the outcomes of TB disease; 
– BCG vaccine and new TB vaccines under development; and 
– the approaches taken by others when conducting an economic 
evaluation, employing modelling, of a TB-related intervention, 
specifically, or other vaccines, generally. 
Literature was identified by searching PUBMED and Google Scholar and 
through using the references cited in the articles identified.  Given the limited 
amount of information available in the formal literature, Google was also 
employed to search for grey literature, such as presentations and reports. 
The literature contributed to an understanding of tuberculosis and the global 
impact of this disease and informed the development of the model structure 
as well as the identification of model parameters. 
What follows is a summary of the literature as it pertains to the research topic 
as well as different aspects of the model.  The first section provides an 
overview of the current global and South African TB situation; from there we 
explain what TB is and some of the challenges in addressing it; before going 
on to describing TB in children.  The second section looks at the history of TB 
control globally, the existing tools for preventing and combatting the disease, 
and the tools currently under development.  Section three summarises the 
role of economic evaluation, including the use of modelling, in the evaluation 
of vaccines.  It briefly touches on aspects such as discounting and 












evaluations and their role in decision making.  We conclude with a summary 
of the review. 
Global Tuberculosis Report 2012 with a focus on South Africa 
According to the World Health Organization (WHO) Global Tuberculosis 
Control Report 2012, “TB remains a major global health problem” and is the 
second foremost cause of death from an infectious disease, second only to 
HIV (World Health Organization 2012). 
In 2011, worldwide, there were an estimated 8.7 million incident cases of TB, 
12 million prevalent cases, and 1.4 million deaths associated with TB.  
Approximately 13% (1.1 million) of incident cases occurred in HIV-positive 
individuals; 79% of which were from Africa.  Of the 1.4 million deaths, 
990,000 occurred in HIV-negative individuals and 430,000 in HIV-positive 
individuals (World Health Organization 2012). 
There were 5.8 million case notifications, representing 66.67% of incident 
cases.  China and India accounted for 40% of these notifications and Africa 
24%, of which South Africa accounted for 25%.  It is estimated that 88% of 
the 5.8 million cases notified occurred in the age group 15–64 years and 6% 
among children <15 years (World Health Organization 2012). 
Since 2000, 22 countries have been identified by WHO as “high TB burden 
countries” and have been prioritised globally for support.  These 22 countries 
contribute approximately 80% of TB cases worldwide.  South Africa is 
included in the 22 countries and, in 2011, was one of five countries with the 
highest number of incident cases; the others being China, India, Pakistan, 
and Indonesia (World Health Organization 2012). 
Compared to the global incidence of TB of 125 per 100,000 population in 
2011, South Africa had an incidence of 993 per 100,000 population.  This 
translates into roughly 500,000 new cases each year.  Approximately 65% of 













South Africa is also one of 27 high MDR-TB burden countries.  Approximately 
1.8% of “new TB cases” have MDR-TB and 6.7% of “previously treated TB 
cases” have MDR-TB.  This compares with the global estimates of 3.7% and 
20%, respectively (World Health Organization 2012). 
Tuberculosis (TB) 
Tuberculosis (TB) is an airborne infectious disease mainly caused by 
Mycobacterium tuberculosis (M tuberculosis).  It is spread by people, who 
have active pulmonary TB disease, when they cough or sneeze; releasing 
the Mycobacterium into the air.  If inhaled, the bacillus is deposited in the 
alveoli of the lungs where it elicits a localized immune response.  The bacilli 
may be destroyed or contained at this point or may spread via the local 
lymphatic system or bloodstream to other parts of the body such as the brain 
and bones.  If the bacilli spread, a systemic immune response occurs.  The 
body can either contain the bacilli – which results in latent TB infection – or 
can fail to arrest proliferation in which case the bacilli rapidly multiply and the 
individual progresses to disease.  It is also possible for an individual to have 
latent TB, which is reactivated (endogenous reactivation) at a later stage due 
to a variety of reasons including suppression of the immune system or for an 
individual to be reinfected (exogenous reinfection) (Dye, Floyd 2006, 
Vynnycky, Fine 1997). 
The major type of TB disease is pulmonary TB.  However, other forms of TB 
exist such as miliary TB, TB meningitis, TB of the kidney, and TB in the 
bones and joints.  These forms of TB are classified as extrapulmonary TB 
(Dye, Floyd 2006). 
TB remains a complex disease.  Despite the discovery of the bacillus in 1882 
by Robert Koch, relatively little is known of the bacillus and the human 
immune response to it.  This lack of understanding poses challenges to the 
development of new tools for prevention, diagnosis, and treatment.  However, 












and how the immune system responds to the organism grows (Lawn, Zumla 
2011). 
The sequencing of the M tuberculosis genome in the late 1990s was 
considered a major breakthrough as it led to the discovery of specific 
antigens, which have now been targeted in the development of new 
diagnostic tests and vaccines as well as the identification of biomarkers for 
tuberculosis (Lawn, Zumla 2011, Hussey, Hawkridge et al. 2007, Collins, 
Kaufmann 2001, Ziv, Daley et al. 2004). 
Not everyone who breathes in the infectious particles will become infected 
with TB and, of those infected; only a small proportion of people will actually 
develop TB disease.  It is estimated that, worldwide, there are 2 billion people 
latently infected with M tuberculosis (Lawn, Zumla 2011). 
It is estimated that only about 30% of those xposed to M tuberculosis will 
actually become infected (McShane 2009).  Amongst those infected, there is 
a 10% lifetime risk of developing TB disease; however, this increases to a 10% 
annual risk in those who are infected with the human immunodeficiency virus 
(HIV).  The 10% lifetime risk is also not evenly distributed – there is an ebb 
and flow in progressing to TB disease – it is approximately 5% in the first 
18–24 months after initial infection and then approximately 5% for the 













Figure 1: Risk of infection and progression to disease and the associated 
risk factors (taken from (Collins, Kaufmann 2001)) 
 
 
This demonstrates that a natural resistance and herd immunity to TB disease 
exists (Young, Dye 2006).  This fact alone makes TB different from other 
vaccine preventable diseases (McShane 2009, Marais 2008). 
TB exists as various health states such as primary TB infection, latent TB, 
TB reactivation, and active disease.  These states exist on a continuous 
spectrum and not as discrete health states (Lawn, Zumla 2011, Lin, Flynn 
2010).  They are affected by, amongst other things, the status of the host’s 
immune system and the mycobacterial bacillary load (Lawn, Zumla 2011).  
The mechanisms associated with reactivation and reinfection are not well 
understood and the risks associated with infection and progression to 
disease appear to be age-dependent and vary over time (Vynnycky, Fine 
1997, Marais, Gie et al. 2004a, Flynn, Chan 2001). 
There is a lack of consensus as to whether TB can be eliminated from the 
body with the currently existing tools or whether, once infected, a person will 












The Annual Risk of Infection (ARI) is the probability of acquiring TB infection 
or TB re-infection over a period of one year.  The ARI is derived from data 
generated through tuberculin skin test (TST) surveys among children.  There 
is a lack of consensus about whether age-specific ARIs exist and whether the 
ARI for new infections is the same as for reinfection (Marais, Gie et al. 
2004a). 
While data on the risk of infection and the risk of progression to disease 
exists, no data on the risk of reactivation has been identified.  This is partially 
due to the inability of scientists to differentiate between recent infection and 
reactivation of latent infection with existing diagnostic technologies (Lin, 
Flynn 2010, Marais, Parker et al. 2009). 
TB generally affects adults in the economically productive age groups (age 
15–49 years) and men are more likely to develop TB than women (World 
Health Organization 2011a).  The morbidity and mortality associated with TB 
constitutes a significant economic burden for individuals, families, and 
countries (Laxminarayan, Klein et al. 2007). 
Studies have also shown that TB is strongly associated with socioeconomic 
status (Davies 2005, Lienhardt, Fielding et al. 2005, Rasanathan, 
Sivasankara Kurup et al. 2011, Shetty, Shemko et al. 2006)(Marais, Obihara 
et al. 2005).  In 2005, WHO developed guidance on how TB programmes 
could include measures for addressing poverty as one dimension of TB 
control.  In its guidance, WHO stated “while TB is not exclusively a disease of 
the poor, the association between poverty and TB is well established and 
widespread” and represented the vicious cycle between TB and poverty 












Figure 2: The vicious cycle between TB and poverty 
 
Childhood TB 
TB in children provides an indirect measure of how well the TB control 
programme is functioning as it signifies recent transmission in the community 
(Marais, Obihara et al. 2005, Nelson, Wells 2004).  The true extent of the 
burden of TB disease in children is not known (Nelson, Wells 2004, Kabra, 
Lodha et al. 2004, Swaminathan, Rekha 2010)(Donald 2002), but it is 
estimated to be around 490,000 cases and 64,000 deaths, annually (World 
Health Organization 2012).  Childhood TB remains a relatively neglected 
disease as children are not considered infectious and, therefore do not 
contribute significantly to the burden and spread of the disease (Marais, 
Obihara et al. 2005, Swaminathan, Rekha 2010, Marais, Gie et al. 2006, 
Brent, Anderson et al. 2008, Donald, Maher et al. 2007).  However, once 













Infants – defined as 0–12 months – have the highest risk of progression to 
disease after infection.  Children infected between the ages of 1–5 years 
remain at relatively high risk of progression; whereas children infected 
between the ages between 5–10 years have the lowest level of risk in 
children.  After 10 years of age, the risk of progression to disease and the 
type of TB disease mimics that of adolescents and adults (Marais, Gie et al. 
2004a, Nelson, Wells 2004, Marais, Gie et al. 2006, Marais, Gie et al. 2004b, 
van Rie, Beyers et al. 1999, Moyo, Verver et al. 2010, Mandalakas, 
Hesseling et al. 2013). 
The accurate diagnosis of TB in children is generally difficult to establish as 
children tend to have paucibacillary TB and are commonly unable to produce 
sputum, which is the necessary for traditional smear microscopy as well as 
newer diagnostic technologies.  Therefore, the majority of children are 
treated based on clinical symptoms, patient history and a high degree of 
suspicion (Marais 2008, Nelson, Wells 2004). 
Children tend to develop TB disease after infection more rapidly than adults 
and develop the more severe forms of TB such as miliary TB and 
TB meningitis resulting in significant morbidity and mortality (Nelson, Wells 
2004, Swaminathan, Rekha 2010, Donald 2002, Brent, Anderson et al. 2008).  
It is only recently that public health officials have begun to look at 
child-friendly diagnostics and medicines as well as child-friendly treatment 
regimens. 
In adults the notion of reactivation of latent TB exists; however, this does not 
seem to be relevant to children (Marais, Parker et al. 2009).  The primary 
mode of TB disease is from TB infection and TB reinfection (Marais, Parker 
et al. 2009). 
Information on childhood TB remains limited.  A review of the literature 
revealed a fair amount of information from the pre-chemotherapy era.  
However, very little information is available, particularly from developing 
countries, about childhood TB in the chemotherapy era; how these disease 












History of TB Control 
The steady decline in TB mortality in industrialized countries in the 20th 
century is attributed to improvements in socioeconomic conditions, better 
nutrition and living standards, and the isolation of infection patients coupled 
with the discovery of the Bacillus Calmette-Guérin (BCG) vaccine in 1921 
and the discovery of various antibiotics to treat TB from the 1940’s.  The 
advent of HIV and multi-drug resistant TB in the 1980’s and 1990’s resulted 
in TB control efforts being hampered.  The significant increase in the burden 
of TB disease in developing countries in the early 1990’s is attributed to HIV 
co-infection, the emergence of drug resistance, and, in the eastern European 
region, to the collapse of the Soviet Union (Lienhardt, Glaziou et al. 2012). 
In 1991, the World Health Organization (WHO) at its Forty-fourth World 
Health Assembly (WHA), recognizing the global increase in new cases and 
deaths related to tuberculosis (TB), adopted a new strategy for addressing 
TB in countries and established two t rgets to be attained by 2000: to 
diagnose 70% of all people with infectious TB, and to cure 85% of those 
diagnosed.  The new strategy comprised of 5 core elements and reflected the 
change to “short-course” regimens and the adoption of “directly observed 
therapy” and became known as DOTS (directly observed therapy, short-
course).  In 1993, WHO declared tuberculosis  a global public health 
emergency and published its first annual TB Control Report in 1997 
(Lienhardt, Glaziou et al. 2012). 
At its Fifty-third WHA, in 2000, Member States acknowledged that the targets 
would not be achieved and deferred their achievement to 2005.  The WHA 
also endorsed the establishment of the Global Partnership to STOP TB 
(STOP TB Partnership) which brings together stakeholders in support of 
strategies that will help achieve the targets.  Furthermore, the Millennium 
Declaration in 2000 established the 8 Millennium Development Goals (MDGs) 
to be achieved by 2015.  In response to MDG 6, the STOP TB Partnership 












The STOP TB Partnership’s ultimate goal is the elimination of TB as a public 
health concern by 2050 (Lienhardt, Glaziou et al. 2012). 
In 2006, WHO together with the STOP TB Partnership, launched an updated 
STOP TB Strategy consisting of 6 pillars, including the need for the 
development of new tools for the prevention, detection, and treatment of TB 
(World Health Organization 2006b). 
Up until the mid-1990’s it was widely believed that the existing tools for the 
prevention, detection, and treatment of TB were sufficient and that they need 
to be applied consistently and at a larger scale in order to achieve the MDG 
targets as well as the goal of elimination (Lienhardt, Glaziou et al. 2012).  
Slowly, individual groups began recognizing that new tools would be 
necessary, especially given the emerging challenges of TB/HIV co-infection 
and drug resistant TB.  In the mid-2000’s, modelling studies confirmed that 
existing strategies alone would not be sufficient to achieve the 2050 target of 
elimination of TB as a public health concern.  It was recognized that new 
strategies for prevention (e.g. new tools for diagnosis and a new vaccine) 
and treatment (e.g. shorter, more effective regimens) would be needed (Dye, 
Garnett et al. 1998) (Abu-Raddad, Sabatelli et al. 2009).  Particularly, it was 
acknowledged that new vaccines that both prevented infection (pre-exposure) 
and disease (post-exposure) progression are needed (Young, Dye 2006). 
Currently existing tools 
Isoniazid Preventative Therapy (IPT) 
Isoniazid preventative therapy (IPT) is recommended in children <5 years 
(World Health Organization 2006a)and HIV-positive individuals who are 
infected with TB, but do not have active TB disease (World Health 
Organization 2011b). 
Isoniazid preventative therapy decreases the risk of progression to active TB 
disease.  No data has been identified, which suggests that IPT can 












TB Vaccine – BCG 
The bacillus Calmette-Guérin (BCG) vaccine was discovered by French 
bacteriologist, Albert Calmette and French veterinarian, Charles Guérin and 
first administered in 1921 (Lienhardt, Glaziou et al. 2012, McShane 2011).  It 
was incorporated into the expanded programme on immunization (EPI) in 
1974 (Lienhardt, Glaziou et al. 2012).  It is one of the most widely used 
vaccines; being administered in the majority of countries worldwide.  In 2011, 
global coverage at birth with BCG was at 90.88% (UNICEF, WHO 2012). 
The BCG vaccine is a live attenuated vaccine and is, currently, the only 
vaccine against tuberculosis (Hussey, Hawkridge et al. 2007). 
In the early 1990’s, two separate meta-analyses of the published literature on 
BCG vaccination were published. 
The first paper, published in 1993, reflected the inclusion of ten randomised 
control trials and eight case-control studies.  The meta-analysis looked at the 
protective effect of BCG against pulmonary TB and against meningeal and 
miliary TB.  For pulmonary TB, it was not possible to calculate a summary 
measure from either the randomised control trials or the case-control studies 
as the results from these studies were so disparate showing a protective 
effect from negative to 100%.  However, for miliary and meningeal TB, the 
protective effect from randomised control trials was 86% and from case-
control studies was 75% (Rodrigues, Diwan et al. 1993). 
The second paper, published in 1994, included fourteen prospective trials and 
12 case-control studies.  The summary effect from the prospective trials 
showed an overall protective effect against TB of 51%, a protective effect of 63% 
against pulmonary TB and 71% against death from TB.  The results of the 
case-control studies showed an overall protective effect against TB of 55%, a 
protective effect of 50% against pulmonary TB, 64% against meningeal TB, 
and 78% against disseminated TB (Colditz, Brewer et al. 1994). 
In 2006, a paper published by Trunz, Fine, and Dye used the data from these 












TB meningitis and miliary TB and found it to be 73% and 77%, respectively 
(Trunz, Fine et al. 2006). 
Overall, the data on BCG’s efficacy in preventing disease progression to 
pulmonary TB after initial infection is highly varied – ranging from 0–80%.  
However, generally, there is consensus that BCG does provide protection 
against severe forms of TB, including miliary and meningeal TB. 
The reasons for the varied effect of BCG that have been put forward include 
differences between the different brands of the vaccine, population 
differences in exposure to environmental mycobacteria, human genetics, and 
differences between different strains of M tuberculosis (Fine 1995, 
Department of Vaccines and Biologicals 1999). 
Due to BCG’s efficacy in preventing severe forms of TB, WHO, in 2004, 
recommended that countries should continue to give BCG to all neonates at-
birth in countries with a high prevalence of TB as well as to children in 
high-risk groups in low TB prevalence countries (World Health Organization: 
Weekly Epidemiological Record 2004).  In 2007, WHO updated this 
recommendation to exclude children who are known to be HIV-infected due 
to the increased risk of disseminated TB disease (World Health Organization: 
Weekly Epidemiological Record 2007). 
No data on BCG’s ability to prevent TB infection has been identified. 
Historically it was thought that BCG did not directly impact on the risk of 
dying from TB; rather it decreased the risk of developing disease and, 
therefore, indirectly contributed to lowering the number of TB deaths.  
Recently, a few studies have been published from the West Africa region, 
which suggests that BCG may also have a direct effect on lowering all-cause 
mortality (Aaby, Roth et al. 2011, Roth, Stensballe et al. 2006); although the 
findings of these studies are disputed (Fine, Smith et al. 2012). 
There is inconsistent evidence on the duration of protective effect offered by 
BCG as well as whether this protection is consistent or whether it declines 












control trials, concluded that “there is not good evidence that BCG provides 
protection more than ten years after vaccination”.  This same paper showed 
mixed results regarding consistency in protection – of the ten papers 
reviewed, seven showed a declining efficacy over time and three showed an 
increase in efficacy (Sterne, Rodrigues et al. 1998). 
There is no evidence to suggest that revaccination with BCG enhances its 
effectiveness or extends its duration of protectiveness (McShane 2009, 
Rodrigues, Pereira et al. 2005).  For this reason, WHO does not recommend 
giving booster doses of BCG (World Health Organization 2006a). 
Despite the controversies on the effectiveness of BCG and its role in TB 
control, a cost-effectiveness analysis of the effect of BCG vaccination on 
TB meningitis and miliary TB, conducted in 2006, declared it to be “highly 
cost-effective” (Trunz, Fine et al. 2006).  A review of published economic 
evaluations involving vaccination against TB, including potentially new 
vaccines, also concluded that universal BCG vaccination, in developing 
countries with a high burden of TB, is cost effective (Tu, Vu et al. 2012). 
TB Treatment 
Treatment for TB is also a relatively new innovation.  The first medicines – 
Streptomycin and Para-aminosalicylic acid (PAS) – for the treatment of TB 
were discovered in 1944.  Based on the results of a clinical trial conducted by 
the UK Medical Research Council, dual therapy was introduced in the late 
1940’s.  Shortly thereafter, Isoniazid was discovered and triple therapy was 
introduced.  Ethambutol replaced PAS in the 1960’s and Rifampicin was 
introduced in the 1970’s.  Pyrazinamide replaced Streptomycin in the 1980’s.  
These changes allowed for the introduction of short-course treatment 
involving Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, and, in some 
cases, Streptomycin for drug susceptible TB; reducing the duration of 
treatment from 18–24 months to 6–8 months (Lienhardt, Glaziou et al. 2012).  
Short-course treatment using standardized regimens remains the 












The first treatment guidelines for MDR-TB treatment were issued in 1997 by 
WHO and relied on medicines not being used for drug susceptible TB, but 
which demonstrated bactericidal and bacteriostatic activity against 
M tuberculosis (World Health Organization 1997).  Since then one or two new 
fluoroquinolones have been added, but, besides, there have been no new 
developments. 
New tools under development 
“The establishment of the Bill & Melinda Gates Foundation (in 1994) 
coincided with the establishment of other public–private partnerships that 
have played a major part in resurrecting TB research and development.” 
(Lienhardt, Glaziou et al. 2012)  As of today, the Bill & Melinda Gates 
Foundation provides funding support for TB drug development (e.g. through 
The Global Alliance for TB Drug Developm nt), for new TB diagnostics  
(e.g. through FIND – the Foundation for Innovative New Diagnostics), and for 
new TB vaccines (e.g. through AERAS and the TB Vaccine Initiative (TBVI)). 
New medicines 
New medicines to treat both drug susceptible and drug resistant TB are 
needed because current regimens involve taking a significant number of 
tablets; treatment courses are long; medicines have significant side-effects; 
some of the existing medicines are not compatible with antiretroviral 
treatment; are not appropriate for children; and do not address latent TB 
infection. 
As of November 2012, there were 8 molecules in pre-clinical development, 












Figure 3: Global TB Drug Pipeline (http://www.newtbdrugs.org/pipeline.php)  
 
New diagnostics 
The increasing numbers of TB cases due to the emergence of HIV and drug 
resistant TB means that new diagnostics are needed in order to speed up the 
detection of both drug-susceptible and drug-resistant TB and to determine 
what TB medicines the bacillus is resistant to.  A number of new diagnostic 
















According to the STOP TB Partnership’s Working Group on new TB vaccines, 
two or three different vaccines are needed to address the different challenges 
of TB Control.  A vaccine is not only needed to prevent infection with 
M tuberculosis (pre-exposure vaccine), but given the extent of existing latent 
infection (almost a third of the world’s population) and low efficacy of BCG 
vaccine, new vaccines to boost existing BCG or to replace BCG that prevent 
progression to disease as well as vaccines to act as an adjunct to treatment 
to shorten the duration of treatment and increase its effectiveness, are also 
needed. 
The vaccines that are the most advanced in their development can be 
broadly classified according to two categories: 
1. Live attenuated vaccines; and 
2. Subunit vaccines. 
The first category looks at replacing the existing BCG vaccine through either 












category looks at boosting the efficacy of the current BCG vaccine (McShane 
2011, Kaufmann, Hussey et al. 2010, Rowland, McShane 2011). 
As of 2011, 12 vaccine candidates were in various states of clinical studies 
(Figure 5). 





One vaccine candidate currently being developed is MVA85A.  MVA85A is a 
“post-exposure” subunit vaccine that is designed to boost the immunological 
response of BCG.  MVA stands for “modified vaccinia Ankara”, which is the 
delivery system used to present the mycobacterial antigen 85A to the 
immune system.  It has undergone a number of Phase I and Phase II Clinical 
Studies which has shown that it is well tolerated, has no significant safety 
concerns, is highly immunogenic, and is effective in increasing the immune 
response to antigen 85A in people who have previously been vaccinated with 













The findings of a Phase IIb Clinical Study conducted in South Africa involving 
HIV-negative infants, where MVA85A was given at 4–6 months as a booster 
to the BCG vaccine, were published in February 2013.  The results of this 
study were disappointing; showing an efficacy of only 17.3% (Tameris, 
Hatherill et al. 2013). 
Economics 
Economics is a social science that studies the production, distribution, and 
consumption of goods and services by individuals, governments, and 
societies in the presence of scarcity.  Given that people, governments, and 
societies tend to always want more than is available, it analyses how choices 
are made in allocating scarce resources to maximize welfare (Guinness, 
Wiseman 2011, Haycox, Noble 2009). 
Health Economics 
Health Economics is a sub-discipline of Economics.  It uses the methods and 
theories from Economics to analyse the healthcare industry (Guinness, 
Wiseman 2011, Haycox, Noble 2009). 
Economic Evaluation 
Economic Evaluation is one tool that can be used, by decision makers, to 
compare alternative approaches to addressing the same problem by looking 
at the costs and outcomes of each (Drummond 2005).  Economic Evaluation 
aims to either maximize health gains from a specified basket of resources or 
to achieve a predefined result for the least amount of resources (Haycox, 
Noble 2009).  There are four types of “full” economic evaluations.  Each type 
assesses costs in a similar manner, but differs in the way outcomes are 
measured and valued (Drummond 2005). 
A Cost Minimization Analysis (CMA) is used if evidence exists that shows the 
two alternatives being compared produce exactly the same outcomes.  This 












comparing medicines from the same pharmacological class.  In this case, the 
choice between alternatives can be made based purely on a cost comparison 
and the least costly alternative would be chosen.  There is controversy on 
whether, or not, a CMA is a full or a partial economic evaluation (Drummond 
2005). 
A Cost Effectiveness Analysis (CEA) is an economic evaluation in which 
health outcomes are expressed in natural units (e.g. patients cured, 
infections avoided, lives saved) and the results are expressed as the “cost 
per unit of outcome”.  CEA is an appropriate framework to compare two 
interventions where one is the current standard of care and the other is a 
new intervention, as it provides information on the relative value provided by 
the “innovation”.  A CEA addresses questions of technical efficiency as it 
compares alternative ways of achieving the same objective (Drummond 2005, 
Gray, Clarke et al. 2011). 
A Cost Utility Analysis (CUA) is similar to a CEA except that it incorporates 
the idea of quality into the outcome measure.  Generally, the outcomes are 
measured as quality adjusted life years (QALYs) or disability adjusted life 
years (DALYs).  QALYs consider not only the quantity of life years gained 
from an intervention, but also the quality of these life years gained.  CUA is 
useful when quality of life is an important outcome, for example when looking 
at different options for cancer treatment.  By changing natural units into a 
common unit of measure, it is possible to compare interventions across 
different diseases.  In this way a CUA can address questions of not only 
technical efficiency, but of allocative efficiency, too (Guinness, Wiseman 
2011, Drummond 2005). 
A Cost Benefit Analysis (CBA) values health outcomes in monetary terms.  
This method is not often used in the evaluation of health programmes as 
people tend to have difficulty in valuing health and human life in monetary 
terms.  As all outcomes are measures in monetary terms, it is possible to use 













When conducting an economic evaluation it is important to decide up-front 
the perspective or viewpoint from which the study will be undertaken.  These 
may range from a narrow perspective of the Ministry of Health or individual 
patients to the broadest perspective being that of society.  The viewpoint 
chosen will impact on which costs are included in the costing of interventions 
(Drummond 2005). 
Decision Analytic Modelling 
Decision analytic modelling can be used when there is insufficient evidence 
available from a single source on which to base a decision and there is 
uncertainty on which course of action to pursue (Drummond 2005).  In 2003, 
the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR), through its task force on Good Research Practices for Modelling 
Studies, defined a health care evaluation model as “an analytic methodology 
that accounts for events over time and across populations, that is based on 
data drawn from primary and/or secondary sources, and whose purpose is to 
estimate the effects of an intervention on valued health consequences and 
costs” (Weinstein, O'Brien et al. 2003).  A model, thus, allows for the 
synthesis of evidence on outcomes and costs by providing a structure in 
which evidence from a variety of sources can be incorporated, allowing for 
the extrapolation of data beyond the trial follow-up period, and allowing for 
the inclusion and management of uncertainty (Drummond 2005, Gray, Clarke 
et al. 2011, Briggs, Claxton et al. 2011). 
In the case of this study, decision analytic modelling in the case of new 
vaccines allows us to extend the costs and outcomes of the two interventions 
beyond the trial time horizon of 2 years. 
In employing decision analytic modelling in cost effectiveness analyses we 
acknowledge that the purpose is to aid decision making rather than provide 
an explicit and absolute result (Gray, Clarke et al. 2011, Briggs, Claxton et al. 
2011).  This is due to the inherent subjective nature of models.  When 












include assumptions on the structure of the model, the parameters chosen 
and their respective values, and value judgements, for example which 
parameters to vary during sensitivity analyses.  A well conducted study will 
present these assumptions transparently and will express any conclusions as 
being dependent upon the assumptions made. 
ISPOR listed a number of principles as “good practice” when using models 
for economic evaluation (Weinstein, O'Brien et al. 2003). 
Markov models 
Markov models are a particular type of decision analytical model (Briggs, 
Claxton et al. 2011).  According to Sonneberg and Beck, Markov models “are 
useful when a decision problem involves risk that is continuous over time, 
when the timing of events is important, and when important events may 
happen more than once” (Sonnenberg, Beck 1993).  These complex 
interrelated aspects are difficult to analyse through a standard decision tree.  
Markov modelling is an appropriate framework for modelling childhood TB as 
TB is a chronic infectious disease which has a number of possible and 
recurring health states with transition probabilities that vary with age. 
Markov models require that discrete and mutually exclusive health states be 
defined.  Patients can only be in one health state at any given time and 
transitions between health states are governed by defined probabilities that 
are either constant or vary over time.  The cycle length and time horizon of 
the model should reflect the natural course of the disease.  Each health state 
is associated with a cost and a reward.  These accrue at the end of each 
cycle and the cumulative result represents the costs and outcomes of each 
intervention once the model has finished running (Gray, Clarke et al. 2011, 
Briggs, Claxton et al. 2011, Sonnenberg, Beck 1993, Briggs, Sculpher 1998). 
Discounting 
It is generally accepted that for studies with a time-horizon of longer than 












This is because individuals do not value costs and outcomes that occur in the 
future the same way as those that occur immediately.  Discounting allows for 
the future costs and outcomes to be presented at present day value 
(Drummond 2005).  There is no consensus on which discount rate to use, 
whether the same discount rate should be applied to both costs and 
outcomes, and whether the discount rate should vary over time or remain 
constant (Severens, Milne 2004, Torgerson, Raftery 1999, Langer, Holle et al. 
2012).  A review in 2000 of 147 studies showed that the same discount rates 
were used for both costs and outcomes and that the rate ranged from 1–8%, 
with the most frequent being 3% and 5% (Smith, Gravelle 2000)(Smith, 
Gravelle 2000). 
Cost-Effectiveness Threshold 
Cost-effectiveness thresholds were first proposed by Weinstein and 
Zeckhauser in 1973.  They proposed that for a given fixed budget in 
situations of perfect divisibility and constant returns to scale of all 
programmes, it is possible to specify a critical ratio – termed lambda – at 
which point all programmes equal to or less than should be implemented 
(Gafni, Birch 2006).  This theory has been criticized due to its impracticality in 
implementing it in the healthcare sector (Gafni, Birch 2006).  
Advocates of the threshold note that the threshold reflects the amount of 
money a particular entity, country, or region is willing to spend for the 
outcome received.  The threshold can either be a fixed value or a range of 
values.  They consider that the thresholds provide a practical way to 
objectively and transparently assess new technologies in a consistent 
manner (Shillcutt, Walker et al. 2009). 
Countries with defined, either implicitly or explicitly, thresholds include (Gafni, 
Birch 2006, McCabe, Claxton et al. 2008, Devlin, Parkin 2004, Bridges, 
Onukwugha et al. 2010): 












 UK (British Pounds 20,000 – 30,000) 
 Canada (Canadian Dollars 20,000 – 100,000) 
The WHO convened, Commission on Macroeconomics and Health, has also 
proposed the following (World Health Organization CHOICE 2012): 
 Interventions are considered to be highly cost-effective at less than 
GDP (Gross Domestic Product) per capita; 
 Cost-effective at 1–3 times GDP per capita; and 
 Not cost-effective at more than 3 times GDP per capita. 
However, they remain controversial as the establishment of a particular 
threshold is “a value judgement that depends on several factors” such as 
“who is making the decision; what the purpose of the analysis is; how the 
decision maker values health, money, and risk; and what the available 
resources are” (Owens 1998). 
The main argument against threshold values is that there is no rational basis 
for the current values (Gafni, Birch 2006, Shillcutt, Walker et al. 2009, 
Bridges, Onukwugha et al. 2010). 
South Africa is in the initial stages of implementing pharmacoeconomic 
evaluation.  The guidelines were issued at the beginning of 2013 
(Department of Health: Republic of South Africa 2013).  The guidelines do 
not state how decisions on cost-effectiveness will be made. 
Economic Evaluation of Vaccines 
Although immunization remains one of the most cost effective health 
interventions (World Health Organization, UNICEF et al. 2009), a number of 
new vaccines have been launched in the past decade.  These newer 
vaccines are significantly more expensive than their predecessors and policy 
makers need a standardized way of assessing their additional costs and 












In 2008, two publications, providing surprising similar frameworks for 
describing models for cost effectiveness analysis of immunization 
interventions, were published (Immunization 2008, Kim, Goldie 2008).  Most 
notably, WHO, in an attempt to ensure consistency in how new vaccines 
were being evaluated, issued guidance on the standardization of economic 
evaluations of immunization programmes (Immunization 2008). 
These documents describe five basic attributes that health economists 
should consider when designing a model to evaluate a vaccine.  They are: 
1. Whether the risk of being infected is static (stays the same) or 
dynamic (changes over time)? 
2. Whether the transition probabilities are deterministic (established 
and consistent at the population level) or stochastic (random and 
variable)? 
3. Whether simulation occurs at a cohort or individual level? 
4. Whether events occur at discrete intervals or over a continuum? 
5. Whether the model is open (individuals are allowed to enter) or 
closed? 
Methods for the Economic Evaluation of vaccines 
The WHO guidance document from 2008, indirectly, recommends the use of 
Cost Utility Analysis for economic evaluations of vaccines by recommending 
that outcomes be expressed as Disability Adjusted Life Years (DALYs) 
(Immunization 2008). 
A review of published literature involving TB vaccines was conducted in 2012.  
The study identified thirteen articles of which twelve looked at BCG vaccine 
and one looked at BCG and a potential new TB vaccine.  Seven studies 
employed Cost Effectiveness Analysis, five employed Cost Benefit Analysis, 
and one used both Cost Effectiveness and Cost Benefit Analyses.  None 












to the difficulty in obtaining utility values for young children who are generally 
the ones receiving vaccines. 
No published Cost-Effectiveness Analyses of the MVA85A vaccine were 
identified. 
Use of Economic Evaluations 
As the need to contain the ever increasing cost of health care grows, so does 
the need for economic evaluations.  Increasingly governments are requiring 
economic data either prior to the registration of a new product or prior to 
listing a product for reimbursement (Clemens, Garrison et al. 1993).  The 
purpose of these evaluations is to demonstrate the new medicine or vaccine 
represents a reasonable level of “value for money”.  Value for money is a 
“term used to assess whether or not an organisation has obtained the 
maximum benefit from the goods and services it acquires and/or provides, 
within the resources available to it”.  It can be “described in terms of the 
'three Es' – economy, efficiency and effectiveness” (Jackson 2012, Imperial 
College London n.d.).  Figure 6 provides a schematic framework within which 
value for money could be considered. 
Figure 6: Value for Money Framework (UK AID 2011) 
 
As a result, pharmaceutical companies are increasingly investing in the 












The role of Economic Evaluation in decision making 
Economic evaluation is one tool that can assist in decision making.  However, 
other aspects, such as affordability, capacity of the health system to 
implement the new technology, equity, and need (e.g. neglected or rare 
diseases), should also be taken into consideration during the decision 
making process.  In this regard, the results of an economic evaluation remain 
only one factor that should be taken into consideration by decision makers 
when deciding whether to adopt a new technology or approach (Guinness, 
Wiseman 2011). 
Conclusion 
Tuberculosis remains a global health concern even though tools to prevent 
and treat TB have been around since the early 1900s.  The advent of HIV 
and multi-drug resistant TB in the 1980’s and 1990’s resulted in TB control 
efforts being hampered.  Existing tools for the prevention and treatment of 
tuberculosis are old and, largely, ineffective – the BCG vaccine doesn’t 
provide complete protection, diagnostics are slow and not 100% accurate, 
and TB treatment involves taking many tablets over a long period of time, 
some of which, have severe side-effects. 
TB remains a compl x disease.  Despite the discovery of the bacillus in 1882 
by Robert Koch, relatively little is known of the bacillus and the human 
immune response to it.  This poses challenges to the development of new 
tools for prevention, diagnosis, and treatment. 
Since the early 2000’s, the TB community has been working with various 
stakeholders to advocate for new tools to fight the disease.  These include 
new diagnostics (e.g. GeneXpert®), new medicines (e.g. bedaquiline), and 
new vaccines. 
Childhood TB remains a relatively neglected disease as children are not 
considered infectious and, therefore do not contribute significantly to the 












The BCG vaccine is a live attenuated vaccine and is, currently, the only 
vaccine against tuberculosis.  No data on BCG’s ability to prevent TB 
infection has been identified.  Overall, the data on BCG’s efficacy in 
preventing disease progression to pulmonary TB after initial infection is highly 
varied – ranging from 0–80%.  Generally, however, there is consensus that 
BCG does provide protection against severe forms of TB, including miliary 
and meningeal TB. There is inconsistent evidence on the duration of 
protective effect offered by BCG as well as whether this protection is 
consistent or whether it declines over time.  There is no evidence to suggest 
that revaccination with BCG enhances its effectiveness or extends its 
duration of protectiveness. 
From an epidemiological perspective, there is a clear need for a new, more 
effective TB vaccine.  As of 2011, 12 vaccine candidates were in various 
states of clinical studies and a number of vaccines are entering into the final 
phases of development. 
Although immunization remains one of the most cost effective health 
interventions, a number of new vaccines have been launched in the past 
decade.  These newer vaccines are significantly more expensive than their 
predecessors and policy makers need a standardized way of assessing their 
additional costs and benefits in order to make informed decisions. 
Economic Evaluation is one tool that can be used, by decision makers, to 
compare alternative approaches to addressing the same problem by looking 
at the costs and outcomes of each.  A Cost Effectiveness Analysis (CEA) is 
an economic evaluation in which health outcomes are expressed in natural 
units (e.g. patients cured, infections avoided, lives saved) and the results are 
expressed as the “cost per unit of outcome”.  CEA is an appropriate 
framework to compare two interventions where one is the current standard of 
care and the other is a new intervention, as it provides information on the 
relative value provided by the “innovation”. 
Decision analytic modelling can be used when there is insufficient evidence 












uncertainty on which course of action to pursue.  A model allows for the 
synthesis of evidence on outcomes and costs by providing a structure in 
which evidence from a variety of sources can be incorporated, allowing for 
the extrapolation of data beyond the trial follow-up period, and allowing for 
the inclusion and management of uncertainty.  Markov models are a 
particular type of decision analytical model. 
To-date there is no standardized and widely-recognized model to estimate 
the potential costs and outcomes of new TB vaccines relative to the BCG 
vaccine.  In addition, no studies looking at the potential cost-effectiveness of 
the MVA85A vaccine in any populations or age-groups have been identified.  
This study will contribute to the development of a standardized Markov model, 
which could be used, in the future, to estimate the potential 
cost-effectiveness of new TB vaccines in children between the ages of 
0–10 years.  Furthermore, it will provide information on the potential cost-
effectiveness of the MVA85A vaccine.  Given the disappointing results of the 
MVA85A vaccine clinical trial, this study will predominantly contribute to 
establishing an efficacy threshold for future vaccines. 
There is a paucity of published information available on TB in children, 
including specific data on their risk of infection and their risk of progression to 
disease.  A review of the literature revealed a fair amount of information from 
the pre-chemotherapy era.  However, when this information was compared 
with routinely available data, there appeared to be a disconnect.  A search for 
information from the chemotherapy era, revealed that very little information is 
available, particularly from developing countries; how these disease risks 
have changed and the natural course of childhood TB.  These data, 
preferably by country or by region, are needed to ensure a robust and 
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TB remains the second foremost cause of death from an infectious disease; 
second only to HIV. Existing tools are largely inadequate. It is
acknowledged that new vaccines that both prevent infection (pre-exposure) 
and disease (post-exposure) progression are needed. A number of potential
new TB vaccine candidates have been identified and are, currently, in
Clinical Trials. One such candidate is MVA85A. This study aimed to
examine the potential cost-effectiveness of adding the MVA85A vaccine to
the BCG vaccine in children from the perspective of the South African
Government.
Methods 
The cost-effectiveness was assessed by employing Decision Analytic
Modelling, through the use of a Markov model. The model compared the
existing strategy of BCG vaccination to a new strategy in which infants
receive BCG and a booster vaccine, MVA85A, at 4–6 months of age. The
costs and outcomes of the two strategies are estimated through modelling
the vaccination of a hypothetical cohort of newborns and following them from
birth through to 10 years of age, employing 6-monthly cycles.
Results 
The results of the cost-effectiveness analysis indicate that the MVA85A 
strategy is both more costly and more effective – there are fewer TB cases 
and deaths from TB – than BCG alone.  The Government would need to 
spend an additional USD 1,105 for every additional TB case averted and 
USD 284,017 for every additional TB death averted.  The threshold analysis 
also shows that, if the efficacy of the MVA85A vaccine was 41.361% (instead 
of the current efficacy of 17.3%), the two strategies would have the same 












adding the MVA85A vaccine to the BCG vaccine.  In this case, the 
Government should consider the MVA85A strategy. 
Conclusions 
At the current level of efficacy, the MVA85A vaccine is neither effective nor 
cost-effective and, therefore, not a good use of limited resources. 
Keywords 
Cost-Effectiveness Analysis, new TB vaccine, Markov modelling, Childhood 














TB remains the second foremost cause of death from an infectious disease; 
second only to HIV (World Health Organization 2012). 
Globally, it is estimated that, in 2011, there were 8.7 million new cases and 
12 million prevalent cases of tuberculosis (TB) and 1.4 million deaths 
associated with TB (World Health Organization 2012).  Furthermore, 2 billion 
– or a third of the world’s population – is believed to be latently infected with 
TB (Lawn, Zumla 2011). 
The true extent of the burden of TB disease in children is not known (Kabra, 
Lodha et al. 2004, Swaminathan, Rekha 2010, Nelson, Wells 2004)(Donald 
2002), but it is estimated to be around 490,000 cases and 64,000 deaths, 
annually (World Health Organization 2012). 
The BCG vaccine is, currently, the only vaccine against tuberculosis.  Data 
on its effectiveness in preventing primary infection and disease progression 
to pulmonary TB is highly varied – ranging from 0–80%. However, there is 
consensus that BCG is protective against disseminated forms of TB, 
including military and meningeal TB (Brewer 2000, Colditz, Berkey et al. 
1995, Colditz, Brewer et al. 1994, Fine 1995, Rodrigues, Diwan et al. 1993). 
In the mid-2000’s, modelling studies showed that existing strategies alone 
would not be sufficient to achieve the 2050 target of elimination of TB as a 
public health concern.  It was recognized that new strategies for prevention 
(e.g. new tools for diagnosis and a new vaccine) and treatment (e.g. shorter, 
more effective regimens) would be needed (Dye, Garnett et al. 1998, Abu-
Raddad, Sabatelli et al. 2009).  Particularly, it was acknowledged that new 
vaccines that both prevented infection (pre-exposure) and disease 
(post-exposure) progression are needed (Young, Dye 2006). 
Following the successful sequencing of the Mycobacterium Tuberculosis 
(M.tuberculosis) genome as well as progress in sequencing bacilli 











have been identified and are, currently, in Clinical Trials.  One such 
candidate is MVA85A. 
MVA85A is a “post-exposure” sub-unit vaccine that is designed to boost the 
immunological response of BCG (McShane 2011, Odutola, Owolabi et al. 
2012, Scriba, Tameris et al. 2011). 
Resources for TB control are limited and have been further constrained due
to the global financial crisis. In addition, a number of new vaccines
(e.g. pneumococcal, rotavirus, and human papillomavirus) have been
developed over the past decade which increases the competition for these
limited resources. 
This study aimed to examine the potential cost-effectiveness of adding the
MVA85A vaccine to the BCG vaccine in children from the perspective of the
South African Government. Modelling is employed to estimate the
cost-effectiveness of a new vaccination strategy as it allows us to extend the
costs and outcomes of the two interventions beyond the trial time-horizon
of 2 years.
Methods
Strategies compared in the model
Our study compared two strategies: BCG at birth, which is the current
standard of care in South Africa, and BCG at birth plus a booster vaccine
(MVA85A) at 4–6 months, which is the potential new strategy.
Modelling 
The cost-effectiveness was assessed by employing Decision Analytic 
Modelling, through the use of a Markov model.  Markov modelling is an 
appropriate framework for modelling childhood TB as TB is a chronic 
infectious disease which has a number of possible and recurring health 











A Markov state transition model was developed in TreeAge Pro Suite® 2012 
to reflect the natural course of TB in children.  The model compared the 
existing strategy of BCG vaccination to a new strategy in which infants 
receive BCG and a booster vaccine, MVA85A, at 4–6 months of age 
(Figure 1). 
Eight mutually exclusive health (Markov) states representing the natural
history of tuberculosis (TB) disease in children were used. They are
uninfected, infected, reinfected, pulmonary TB, miliary TB, TB meningitis, 
death all causes, death TB-related (Figure 2). Transitions amongst health
states were permitted according to specific transition probabilities and
specific criteria. Patients could remain in certain health states 
(e.g. uninfected). “Death” was considered to be an absorbing state i.e. once
a patient had entered it, the patient could not leave.
The model is a static, deterministic, closed, and discrete model.
– Static: one Annual Risk of Infection (ARI) has been used for the
entire duration of the model.
– Deterministic: set parameters are used to determine how the cohort
moves through the model.
– Population-based: a single cohort moves through the model.
– Closed: new individuals cannot enter the model over the 10-year 
period.
– Discrete: events occur at 6-monthly intervals.
The costs and outcomes of the two strategies were estimated through 
modelling the vaccination of a hypothetical cohort of newborn children and 
following them from birth through to 10 years of age, employing 6-monthly 
cycles. 
A time horizon of 10 years was chosen as this represents the time period 
over which there is a unique pathway of TB in children.  Beyond 10 years, the 












Age-specific risks for progression to three different TB disease states – 
pulmonary TB (PTB), miliary TB (mTB), and TB meningitis (TBM) – and the 
risk of death from these disease states were reflected in the model together 
with the risk of TB infection.  These data have been taken from the published 
literature, expert opinion, and government data bases such as the South 
African electronic TB (e-TB) register. 
Data on all-cause mortality rates were taken from WHO 2009 Life-Tables 
(World Health Organization Global Health Observatory (GHO) 2012) and 
were adjusted to remove the age-specific risk of dying from one of three 
TB disease states. 
Data on the efficacy of MVA85A was taken from the results of the Phase IIb 
Clinical Trial in Worcester, South Africa, which showed the efficacy rate 
against tuberculosis in infants to be 17.3% (Tameris, Hatherill et al. 2013).  
This cost-effectiveness study was designed before the findings of the vaccine 
efficacy became available. 
The model parameters are reflected in Table 1. 
Model Assumptions 
– All children started out uninfected and, once infected, a child could 
never be uninfected. 
– A single Annual Risk of Infection (ARI) of 3% was used throughout 
the duration of the model, for all age groups, and for both the risk of 
“TB infection” and “TB reinfection”. 
– Three age groups (0–2 years, 3–5 years, and 6–10 years) were 
represented in the model.  These represented the ages at which the 
risks associated with progression to disease and mortality was 
significantly different. 
– The efficacy of BCG vaccine was indirectly included in the model by 
virtue of the fact that the TB data used in the model has been taken 











the 1970’s (van Rie, Beyers et al. 1999) and up-take – defined as the 
proportion of children eligible to receive the vaccine who actually 
receive the vaccine – is in excess of 95% (Corrigall, Coetzee et al. 
2008). 
– The efficacy of BCG remained constant over the 10-year period and
BCG did not have a direct effect on all-cause mortality.
– The drop-out rate between the DTP3 vaccine (given at 14 weeks)
and the MCV vaccine (given at 9 months) was taken as the proxy for
MVA85A vaccine up-take.  Vaccine up-take was used together with
efficacy to calculate the effectiveness.
Excluded from the model 
– Herd immunity, as humans seem to have a natural resistance to
infection with M.tuberculosis and to progression to TB disease, which
doesn’t appear to be further enhanced by the BCG vaccine (Young,
Dye 2006) and is not being studied for the MVA85A vaccine.
– Isoniazid preventive therapy (IPT), as the effect would have been
equal in both arms.
– BCG disseminated disease (a side-effect of BCG vaccination), as the
effect would have been equal in both arms.
Costing method 
Costs were taken from the perspective of the South African Government and 
were calculated using an ingredients-based costing methodology.  All cost 
data, except for the price of MVA85A, was taken from South African data.  
The majority of information has been taken from the costing work down by 
Mandalakas et al (Mandalakas, Hesseling et al. 2013).  These costs, 
available as South African Rand (ZAR) 2009, were inflated using consumer 
price index (CPI) figures (Statistics South Africa 2012a) to 2012 values, and 
then converted to US dollars (USD) at the average exchange rate USD to 












(OETC) provided the cost of MVA85A vaccine in USD.  All costs were 
reflected in 2012 USD. 
The cost for vaccination, diagnosis, and treatment are reflected in Table 2. 
Effectiveness measurement 
As the vaccine was designed to prevent progression from TB infection to 
TB disease, we calculated the absolute difference in the number of TB cases 
and TB deaths between the two interventions i.e. BCG alone versus BCG + 
MVA85A. 
Given that very limited information is available on the utilities associated with 
the various health states for TB in children, as well as the difficulty in 
determining these, the Quality-Adjusted Life-Year (QALY) was not used. 
Cost-effectiveness analysis 
The model was designed to determine the number of TB cases averted and 
the number of TB deaths averted.  At the end of the 10-year period the 
cumulative costs and outcomes of each intervention were used to calculate 
the cost-effectiveness ratio (CER) (i.e. the cost per TB case averted and the 
cost per TB death averted) for each intervention.  These two cost-
effectiveness ratios were compared using an incremental cost-effectiveness 
ratio (ICER), which represent the additional cost per additional benefit 
received. 
Discounting 
Consistent with recommendations and published studies, all future costs and 
outcomes were discounted at 3% (Weinstein, Siegel et al. 1996, Severens, 
Milne 2004, Torgerson, Raftery 1999, Langer, Holle et al. 2012, Smith, 
Gravelle 2000). 
Model Calibration and Validation 
There is no standardized Markov model for the evaluation of new 












However, the structure and model inputs were validated through an expert 
consultation group. 
Dealing with uncertainty 
By its very nature modelling is considered subjective and involves a degree 
of uncertainty (Drummond 2005).  We, therefore, conducted a one-way 
sensitivity analysis to check for uncertainty around the discount rate, 
MVA85A vaccine efficacy, vaccine cost, vaccine coverage, and annual risk of 
infection. 
We also performed a threshold analysis to determine the level of efficacy at 
which the cost of the MVA85A vaccine strategy would equal the cost of the 
BCG strategy, but produce additional benefits. 
Results 
Table 3 represents the discounted and undiscounted 10-year costs, the 
absolute number of TB cases and TB deaths, and incremental cost-
effectiveness ratios (ICERs) associated with adding MVA85A vaccine to the 
existing strategy of BCG at birth, from the perspective of the South African 
Government. 
Both the discounted and discounted results show that adding the MVA85A 
vaccine to the BCG vaccine is both more effective and more costly. 
The base-case scenario reveals ICERs of USD 1,105 per TB case averted 
and USD 284,017 per TB death averted. 
Sensitivity Analyses 
A summary of the sensitivity analyses for key parameters is provided in 
Table 4.  The results showed that the outcomes were robust; being most 
sensitive to the ARI, MVA85A vaccine efficacy, and the MVA85A vaccine 
price. 
The threshold analysis shows that at an efficacy of 41.361%, the MVA85A 












This cost-effectiveness study was designed while the vaccine clinical trial 
was still ongoing.  The recently published results of the Phase IIb Clinical 
Trial conducted in Worcester, South Africa, showed that the efficacy of the 
MVA85A vaccine in preventing TB in infants to be 17.3% (Tameris, Hatherill 
et al. 2013).  Therefore, the vaccine has very poor effectiveness.  This has 
had a noticeable effect on the outcomes of the cost-effectiveness analysis. 
The results of the cost-effectiveness analysis indicate that the MVA85A
strategy is both more costly and more effective – there are fewer TB cases
and deaths from TB – than BCG alone. The Government would need to
spend an additional USD 1,105 for every additional TB case averted and
USD 284,017 for every additional TB death averted.
South Africa is in the initial stages of implementing pharmacoeconomic
evaluation and has not defined an explicit acceptability threshold. However, 
if we consider the recommendations made by the Commission on
Macroeconomics and Health (World Health Organization CHOICE 2012), 
then at South Africa’s GDP per capita of USD 8,070 (World Bank 2013), the
vaccine would be considered highly cost-effective in terms of TB cases 
averted. For TB deaths averted it would, however, not be considered cost-
effective.
Irrespective of these results, our research contributes to the body of 
knowledge on economic evaluations involving new TB vaccines as – to the
best of our knowledge – this is the first cost-effectiveness analysis conducted
using trial data involving a novel TB vaccine and providing a direct
comparison with BCG vaccination.  While economic evaluations involving the
modelling of new TB vaccines have been done, those published, have relied
on assumptions of efficacy (Tseng, Oxlade et al. 2011, Ziv, Daley et al. 2004).
In addition, this study provides a model structure, which could be used for 













The threshold analysis also shows that, if the efficacy of the MVA85A vaccine 
was 41.361% (instead of the current efficacy of 17.3%), the two strategies 
would have the same cost but more cases of TB and more deaths from TB 
would be prevented by adding the MVA85A vaccine to the BCG vaccine.  In 
this case, the Government should consider the MVA85A strategy. 
The sensitivity analyses suggest that the ICER is sensitive to the price at 
which the vaccine will be made available, the annual risk of being infected 
with TB, and the efficacy of the vaccine. 
The limitations of this study arise from the paucity of data on childhood TB 
during the chemotherapy era and our inability to access the full South African 
e-TB register dataset.  For these reasons, parameters have been derived 
from the Western Cape’s e-TB register.  As the Western Cape has the third 
highest number of TB cases in South Africa (Day, Barron et al. 2012), we do 
not believe that this has distorted the results.  The study assumed an annual 
risk of infection of 3% and has applied this to the e-TB register data in order 
to establish the risk of progressing to disease.  It was also assumed that the 
e-TB register data reflected the effectiveness of the BCG vaccine in the 
population given that the Western Cape has routinely administered BCG 
since the 1970’s (van Rie, Beyers et al. 1999) and up-take is in excess of 95% 
(Corrigall, Coetzee et al. 2008). 
Conclusion 
Our findings indicate that, due to its low efficacy, adding MVA85A as a 
booster to BCG against infant and childhood TB is not cost-effective, and, 
therefore, not a viable use of limited resources. 
Nevertheless, our research contributes to developing a standardized Markov 
model, which could be used, in the future, to estimate the potential cost-
effectiveness of new TB vaccines compared to the BCG vaccine, in children 
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Parameters Value Range References 
Risk of death from pulmonary TB (%) 
< 3 years 0.74952 
3-5 years 0.09120 
• Electronic databases (Provincial Government Western Cape 
> 6 years 0.58766 
Risk of death from miliary TB (%) Department of Health 2012, Statistics South Africa 2012b) 
< 3 years 23.52941 
• Calculated using average for 2005-2009 and e-TB data 
3-5 years 9.09091 • Expert opinion 1 
> 6 years 16.66667 
Risk of death from TB meninQitis (%) 
< 3 years 25.00000 
3-5 years 26.66667 
> 6 years 20.00000 
MVA85A efficacy against TB disease (%) 17.3 12.3 - 22.3 • Published literature (Tameris, Hatherill et al. 2013) 
Up-take BCG (%) 99.0 99.0- 99.5 • Published literature (Corrigall, Coetzee et al. 2008, Department of 
Health: Republic of South Africa 2011) 
Up-take MVA85A 85.0 76.4- 89.5 • Calculated 
• Published literature and electronic database (Saloojeei, Bamfordii 
Drop-out rate DTP3 to MCV 14.0 9.5-23.1 2006, Health Systems Trust 2007) 
• Expert opinion 1 
Discount rate outcomes (%) 3 0-6 • Published literature (Weinstein , Siegel et al. 1996, Severens, Milne 
Discount rate costs (%) 3 0-6 2004, Torgerson, Raftery 1999, Langer, Holle et al. 2012, Smith, Gravelle 2000) 
1 Expert opinion provided by: Professor Willem Hanekom, Dr Mark Hatherill, Professor Anneke Hesseling, Dr Helen McShane, Dr Hassan Mohammed, 















































































Number of TB 
deaths 
ICER 








BASE CASE RESULTS 
Discounted (3%) 
BCG alone 84.17 0.09101 0.0003501817 
plus MVA85A 98.23 0.07828 0.0003006626 1,105 284,017 
Undiscounted 
BCG alone 97.65 0.10627 0.0004174069 
plus MVA85A 109.80 0.09138 0.0003583168 816 205,603 
Discounted (6%) 
BCG alone 73.53 0.07885 0.0002969804












Table 4: Effect of differing assumptions on the base-case ICER 
Parameter 
Increase/Decrease in ICER 
(TB cases averted) 
Increase/Decrease in ICER 
(TB deaths averted) 
   
Annual Risk of Infection (ARI)   
2% + 79.86% + 79.71% 
4% - 39.88% - 39.83% 
   
MVA85A vaccine cost1 (USD 
2012) 
  
20.22 - 48.35% - 48.35% 
48.22 + 120.87% + 120.87% 
   
MVA85A vaccine up-take   
76.4% + 0.14% + 0.12% 
89.5% - 0.07% - 0.06% 
   
MVA85A vaccine efficacy   
12.3% + 69.90% + 69.81% 
22.3% - 38.55% - 38.52% 
   
Discounting   
0% -26.15% - 27.61% 
6% 28.14% + 30.72% 
   
                                                          
1 Vaccine price provided by OETC: base-case USD 15 per dose; low USD 7 per dose; 











Figure 1: One arm of the Markov model (BCG + MVA85A) 
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For r ep:::lrting standards pjease see the infonTIation in the .&!.!1 secti on. 
Title page 
The ti tl e page should 
p r ov id e the ti tle of the artide 
list the lUll n ames, ins titiJ tional adctesses and email addresses fo r a ll authors 
ind icate the corTesponding author 
Fi ease note : 
the ti tle should indude the study design, fo r e xample "A versus B in the treatment of c: a randomized control l ed trial X is a r isk factor for Y: a case control 
stiJdy" 
abbreviations withn the title sho[jd be avo id ed 
Abstract 
The Abstrac t of the manusaipt should rot exceed 350 words and must be structured into separ ate sections Background, the context and purpose of the stiJdy; 
Methods, ho ..... the study ..... as per formed an d sta ti stica l t ests used; Resul:s, the main findings; Conclusions, brief summary and p:::ltential impjications. Fiease 
m inim i ze the use o f abbreviations and do not dte references in the abstract. Trial registration, i f your research reports the results of a controlled heal th care 
Intervention, pj ease li st your tri al regi stry, along ..... ith the UliQJe identifying rumber (e .g . Trial registration: Current Controlled Trial s ISRClN73824458) . Fiease 
note that there sho[jd be n o space be tween the letter s an d m.m bers of yOLl"" trial r eg stra tion number. We recommend m anuscrip ts that report randomized 
controlled tri als follow the CONSORT ex tensi on for abstra cts 
Keywords 
Three to ten k ey ..... ords rep r esenting the main content of the artide 
Background 
The Backg-ound secti on should be ..... ri t ten in a ..... a y tha t is accessible ill r esearcher s wi thout spe dal ist kno ..... led ge in tha t area and must d early st ate - and, if h elp fU, 
Il lu stra te - the backg-ound to the research and it s aims. Reports of dincal research should, ..... h er e C(lpl"opri ate, indude a summary of a search of the Ii t eratiJre ill 
Indica te ..... hy th is study ..... as necessary and ..... hat it aimed to contribute ill the field. The se ction shoud end ..... i th a br ief st atem ent o f ..... ha t is being reported in the 
arti d e. 
Methods 
The methods sec tion shoud ind ude the design of the stiJdy, the setting, the type of partidpants o r ma ter ials invdved, a clear descri p tion of all inter venti ons and 
comparisons, and the type of analysis used, induding a po ..... er ca lculation i f appropria te . Generic ctug names shou d genera lly be used . 'Mlen pr opri et ar y brands are 
used in research, indude the brand names in parentheses in the Methods section 
For stiJdies involving ruman partidpants a statem ent detailing ethcal approval and consent shoLi d be induded in the methods section. For tiJther d elBii s of the 
journal 's edtorial policies and ethical gudelines see 'Aboll t thi s p , rnal '. 
For tiJther delDi l s of the j oumal's d ata-l"elease p:::l licy, see the pol ic y section in 'W ilt this iQ! 'ma l' . 
Results and discussion 
The RestJ ts and dSaJssion m ay be combined in to a 9nge sect ion or p resented separatel y. Re stJ ts of stati stical analysi s should indude, ..... here appropria te, re lati ve 
and absdute risks or risk reductions, and con fi dence inte rva ls . The Resu lts and d iscussion sections m ay also be b roken into SLbsections ..... ith short, infonTI ati ve 
head ings 
Conclusions 
This shot..ld sta te d early the main condusions o f the research an d give a dear expj anati on of thei r importrmce and rel evance . Sunmary illustrations may be 
Included. 
List of abbreviations 
I f abbre v iations are used in the te x t they should be defined in the text a t first use , and a list of abbreviations can be provided, which should precede the competing 
Interests and authors' contributions 
Competing interests 
A compe ting in tere st exists ..... hen your interprehltion of data or prese ntation of information may be influ enced by your personal or fi nandal rel ationship wi th other 
p eople or organizations. lluthors must d sdose any fi n arKl al com peting interest s; they should also reveal any non-finandal competing interests that may cause them 
embarTassment were they to becom e public after the publ ication of the manuscript. I 
lluthors are r equ red t o complete a ded ar ation of competing interests. AJ I competing in ter ests that are ded ar ed will b e l ist ed at the end of plillished artide s. Where 
an author gves no competing interests, the listi ng will read 'The author( s) dedare that they have no competing interests' 
When completing your dedaration, ple ase consider the following QJestions 
Financial competing Interests 
I n the past fi ve years have you r ecei ved reimbo.rsements, fees, funding, or sa lary from an o rganizati on tha t may in any way g ain or lo se financia lly from the 
p ubl ica tion of th s m anuscript, ei ther now or in the lUtu:"e? Is such an organ ization fi n ancing this maruscri pt (i nduding the article -processing charge)? I f so, 
p lease specify . 
Do you hold any s tock s or shar es in an o rg an ization that m ay in any way gain o r l ose finandally from the publication of this manuscript , ei ther now or in the 
futiJre? I f so, p lease speci fy . 
Do you h old or are you aJrrently applyi ng for any patents r elati ng to the conten t of the m anuscript? Have you rece iv ed reimbursements, rees, fi.xlding, o r 
salary from an organ ization that holds or h as app lied fo r p atents rel ati ng t o the content of the maruscript7 [ f so, p lease speci fy . 
Do you have any other financial competing interests? I f so, pjease spe dfy 
Non-flnanclal cumpetlng Interests 
Pre there any ron- fi nand al competi ng interests (pol iti ca l, personal, relig ious, id eologica l, academic, inteli ectiJal , commerdal or any other) ill dedare in relation to 
thi s manuscript? I f so, p lease specify . 
I f you are unSlIe as t o ..... hether you, or one YOII co-authors, has a competing in te re st pj ease dscuss it with the e d torial office. 
Authors' contributions 
In order to give appropriate c redi t to e ach author of a paper, the indiVidual contri butions of authors t o the maruscript should be specifi ed in ths section 
I'll 'author' is general ly considered to be someone who has made Slilstantive intell ectual cont ri butions to a published study. To qUdlify as an author one should 1) 
have mad e substantial cOlltributions to conception and design, o r aCqJisition o f daIB, or analysis and interpre tation of dahl; 2 ) have been involv ed in d rafljng the 
maruscript o r revising it cri tical ly for important i n tel lectiJa l content; and 3) have given fina l approva l of the version ill b e published. Each auttor should have 
participa ted sufficlen~y in the work t o IDke p ublic resporlsibility for appropria te portions of the content . AcQJi sition of fi.xldng, coll ection of daIB, or general 












We suggest the fol lo wing k ind of format (plea se use in itial s to r efer to each author's contribution) : P8 carried out the moleCL" ar genet ic studes, partic ipated in the 
sequence ali gnnent and a-a fted the m aruscri pt. JY C3rri ed out the immunoassays, MT partidpated in the sequence alignmen t. ES partidpated in the design of the 
study and performed the sta~ s~C3 1 analysis, FG conce ived o f the study, and par tidpated in it s desigl an d coord nation and helped t o a-aft the m aruscript. ,llI 1 
authors read and approved the fi n al m anuscrip t 
,llI1 contributor3 who d o not meet the criteria fo r authorship should be l isted in an acknowl ed gemen ts section. Example s of those who mi(f1 t be acknowledged include 
a person who p rovided p.Jrely techn ca l h elp, wri tirg assi stance, or a department cha ir who provi ded only g eneral SLpport . 
futhors' information 
You may choose to use th s sect ion to ind ude any relevant information about the author( s) that may aid the read er' s interp-etation of the artide, and mder3tand 
the standpoint o f the au thor(s). Ths m ay indude detail s about the authors' qua li fi C3 ~ onS, UlrTent positions they hold at i nstitiJtions a- societ ies, a- any other 
r el evan t badg-olfid infurmation. Please r e fe r to autha-s using their in itia ls , Note th s sect ion shoul d not be used to describe any competing in ter es ts. 
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Endnotes 
Endnotes should be desiglated wi thin the text u sirg a SLperscript lowercase l etter and all notes (along wi th the ir correspondin g letter ) should be included in the 
Endnotes secti on , Please forma t ttis section in a paragraph r ather than a li st . 
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Preparing illustrations and f i gures 
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portrait forma t . I f a fig.lre consists of separate par ts, it is important that a singe composi t e illustration fil e be stL>mitted wh ich centains a ll parts of the fi gU"e . There 
I s no charge for the u se of cd or fi gJres. 
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PDF (p referred format for d iag-ams) 
OOCX/DOC (sing e page only ) 
PPTx/ppT (single sli de on ly ) 
CPS 





iTlle legerds shoLld be irduded in the m ain manuscript text fil e at the end of the doclJTlent, rather than being a par t of the figure fi le. For each fi g.Jre, the following 
,nformation sh9Ud be provided: Rgl..I"e nlJTlber (in ge'l-Jence, usingkabic rumera ls - i.e. Rg.ore 1, 2, 3 etc); short ti tl e of fi g.Jre ( maximum 15 word s); detai led 
lege nd, ~ t o 300 words 
Please note that it is the responsibility o f the author(s ) to obtain pennission from the copyright holder to reproduce figures or tables that have 
previously been published elsewhere. 
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Earn table should b e numbered and dte d in seQJence using kabic numerals (i .e. Table 1, 2 , 3 etc.) . Tabl es should also have a title (above the tab le) that 
summari zes the whole table ; it should be no l onger than 15 words. Detailed legerds may then fd low, but they should be condse . Tables should always be d ted in 
t ex t in conseU.ltive numerical order 
Smaller tables considered to be integ-al to the marusaipt can be pa sted inlD the end of the doclJTlent text file , in A4 p ortra it or landscape format These wi ll be 
typeset and dsplayed in the fina l pLblished fOrm of the ar~ d e . Such tables should be fOrmatted using the 'Table obj ect' in a word processing p rog-am ID ensure that 
cdumns of data are kept al igned when the fil e i s sen t el ect renica ll y for rev iew; this will not a lways b e the case if columns a re generated by simply using tabs ID 
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to indca te rume riC31 values. Color an d shading may not b e used; parts of the table can be highlighted using symbols o r bd d t ext, the mea ring of wh ich should be 
explained in a table legend . Tabl es should not be embedded as figJres OJ spreadsheet fi les. 
Larger datase ts or tab les \Do wide for a landscape page can be uploaded separate ly as add ~onal files. Pdd~onal fi les wil l n ot be displ ayed in the fi nal, la id-out FVF 
of the ar~ d e , but a lin.: will be provided t o the fi les as suppl ied by the author 
Tabular data provided as ad d tienal fil es can be L.ploaded as an Excel spreadsheet (. >ds) or comma separated value s ( .csv) . As with al l fi les, pl ease u se the stardard 
fi le ex tensiens 
Preparing additional files 
~ th:Jugh Cost Eft'ectJveness and Resource Allocat1on does not restrict the l ength and 'l-Jantity of data induded in an artide, we encourage authors to provide 
datasets, tables, movi es, or other infOrmation as add tiena l fi les 
P1ease note : ~ I Additional fi les will be published aleng with the artide. Do not indtxle fi les such as p atien t censent forms, certifiC3tes o fl ang.oage ed~ng, or 
r evised versions of the main manuscript document wi th tracked changes. Sudl files should be sent by em ail to reSQ! !rce alloC{ltim@bjOOJeci:entral. com 'l-J0ting the 
Maruscri pt 10 rumber 
ResUts tha t wou ld otherwise be indicated as "data not shown" can an d should be ind uded as addilienal fi les. Since many webl inks and URLs rapjdl y become broken, 
Cost Eft'ect1veness and Resource Allocation re'l-Jires tha t supporting data are induded as additional file s, o r d eposited in a recogrized repository . P1 ease do not link 
to data en a p ersonal/departmenta l websi te . The ma4mum fi le size for add tional fi les i s 2 0 MB each, and files wi ll be virus-samn ed en submission 
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Figure 4a: BCG arm_Number of TB cases 
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Figure 4b: BCG arm_Number of TB deaths 
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Figure 5a: BCG + MVA85A arm_Number of TB cases 
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Figure 5b: BCG + MVA85A arm_Number of TB deaths 
Unin fe cted 
- Marl<ov Info rmat ion 
Ini t Cost : (cBCG*uBCG)+(cMVA8SA*uMVA8SA) 
Incr Cost: 0 
f ina l Cost : 0 
Init TB deat hs: 0 
Incr TB deat hs: 0 
f ina l TB deaths: 0 
In fected 
- - Marl<ov Info rmat ion 
Ini t Cost : 0 
Incr Cost: 0 
Fina l Cost : 0 
Init TB deaths: 0 
Incr TB deat hs: 0 
Fina l TB deat hs: 0 
Re -infected 
- - Marl<ov Info rmat ion 
Ini t Cost : 0 
Incr Cost: 0 
Fina l Cost : 0 
Ini t TB deaths: 0 
Incr TB deat hs: 0 
f ina l TB deaths: 0 
em 
- - Marl<ov Info rmat ion 
Ini t Cost : 0.5 * ( discount(cPTBDxTx(Age];cOR;_stage/2)) 
Incr Cost: d iscount (cPTBDxTx[Age [;cDR;_stage/2) 
f ina l Cost : 0.5 * (discount(cPTBDxTxIAge[;cOR;_stage/2)) 
Init TB deaths: 0 
Incr TB deat hs: 0 
Fina l TB deat hs: 0 
mm 
- - Marl<ov Info rmat ion 
Ini t Cost : 0.5 * (discount(cmTBDxTx[Age [;cDR;_stage /2)) 
Incr Cost: d iscount (cmTBDxTxIAge[;cOR;_stage/2) 
f ina l Cost : 0.5 * (discount(cmTBDxTx[Age [;cDR;_stage/2)) 
Init TB deaths: 0 
Incr TB deat hs: 0 
Fina l TB deat hs: 0 
mM 
- - Marl<ov Info rmat ion 
Ini t Cost : 0.5 * (discount(cTBMDxTx[Age [;cDR;_stage /2)) 
Incr Cost: d iscount (cTBMDxTxIAge[;cOR;_stage/2) 
f ina l Cost : 0.5 * (discount(cTBMDxTx[Age [;cDR;_stage/2)) 
Init TB deat hs: 0 
Incr TB deat hs: 0 
Fina l TB deaths: 0 
0 
De ath_ TB disease 
- - Marl<ov Info rmat ion 
Ini t Cost : 0 
Incr Cost: 0 
Fina l Cost : 0 
Ini t TB deaths: 0 
Incr TB deat hs: 0 
f ina l TB deaths: 0 
0 
De ath_ a ll cause 
- - Marl<ov Info rmat ion 
Ini t Cost : 0 
Incr Cost: 0 
Fina l Cost : 0 
Ini t TB deaths: 0 
Incr TB deat hs: 0 
f ina l TB deaths: 0 
Alive 
• 
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prob toprob(pDyirgAiICause [lIge];6/12) 
Alive 
! • 
\ Dead_ a ll cause 
prob toprob(pDyirgAiICause [lIge];6/12) 
Alive 
• 
Dead_ a ll cause 
prob toprob(pDyirgAiICause [lIge];6/12) 
Alive 
! • 
Dead_ a ll cause 
prob toprob(pDyirgAiICause [lIge];6/12) 
Alive 
! • 
Dead_ a ll cause 
prob toprob(pDyirgAiICause [lIge];6/12) 
Alive 
! • 
\ Dead_ a ll cause 
prob toprob(pDyirgAiICause [lIge];6/12) 




Remain in fected 
• 
Become re -infected 
probtoprob(ARI;6/12) 
Pr"8ress to PTB 
prob toprob(pPr"8ressPTB[lIge ];6/12)-{probtoprob(pPr"8ressPTB[lIge ];6/12)O(eMVA8SAOuMVA85A)) 
Pr"8ress to m TB 
probtoprob(pPr"8ressmTB[lIge);6/12)-(probtoprob(pPr"8ressmTB(lIge];6/12) O(eMVA85AOuMVA8SA)) 
Pr"8ress to TBM 
prob toprob(pPr"8 ressTBM[lIge);6/12)-(probtoprob(pPr"8ressTBM(lIge);6! 12)O(e MVA85AouMVA85A)) 
Remain in fected 
! • 
Pr"8ress to PTB 
probtoprob(pPr"8ressPTB[lIge );6/12)-{probtoprob(pPr"8ressPTB[lIge];6/12)O(eMVA85AouMVA85A)) 
Pr"8ress to m TB 
probtoprob(pPr"8ressmTB[lIgej;6/12)-(probtoprob(pPr"8ressmTB(lIge);6/12) O(eMVA85AOuMVA8SA)) 
\ Pr"8ress to TBM 
prob toprob(pPr"8ressTBM[lIge j;6/12)-(probtoprob(pPr"8ressTBM(lIge);6! 12)O(e MVA85AouMVA85A)) 
Cured & re m a in infected 
• 
Cured & immediately re -infected 
probtoprob(ARI;6/12) 
Die from PTB 
I ~- Marl<ov Informat ion 
Trans TB deaths: disccunt(oTBdeath;oDR; stage /2) I 
p robtoprob(pDyirgPTB[lIge];6/12) 
Cured & re m a in infected 
• 
Cured & immediately re -infected 
probtoprob(ARI;6/12) 
Die from mTB 
I ~- Marl<ov Informat ion 
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probtoprob(pDyirgm TB[lIge ];6/12) 
Cured & re m a in infected 
• 
Cured & immediate ly re -infected 
probtoprob(ARI;6/12 ) 
Die from TBM 
I~- Marl<ov Informat ion 
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PREVENTING TB IN CHILDREN IN SOUTH AFRICA 
Is it cost-effective to add the MVA85A vaccine to the BCG vaccine? 
Key points 
 South Africa has a high burden of TB.  Existing tools to prevent and treat TB
are, largely, ineffective.  New vaccines that prevent TB infection and
progression to TB disease are needed.
 MVA85A is intended to enhance the effectiveness of the BCG vaccine and is,
currently, being studied in various Clinical Trials.
 In HIV-negative infants, MVA85A vaccine is not effective in preventing TB
when given as a booster to the BCG vaccine.
 Adding MVA85A as a booster to BCG against infant and childhood TB is not
cost-effective, and therefore not a good use of limited resources.
 A new TB vaccine with an efficacy of, at least, 41.361% would potentially be
cost-effective.
Introduction 
South Africa is considered, internationally, as both a high TB burden country and a high
MDR-TB burden country. Annually, there are an estimated 500,000 new cases of TB, 
of which, approximately 10,000 have MDR-TB. TB/HIV co-infection is a key driver of 
the epidemic (World Health Organization 2012).
The tools for preventing and combatting tuberculosis are old and, largely, ineffective. 
The BCG vaccine doesn’t provide complete protection, the diagnostics are slow and not 
100% accurate, and the treatment involves taking many tablets over a long period of 
time, some of which, have severe side-effects.  Since the early 2000’s, the TB
community has been working with various stakeholders to advocate for new tools to 
fight the disease.  These include new diagnostics (e.g. GeneXpert®), new medicines 











The new TB vaccines being developed are designed to either prevent infection (pre-
exposure vaccine) or to prevent progression to active disease (post-exposure vaccine), 
or both.  South Africa has approved a number of clinical trials, involving new TB 
vaccines.  One such trial took place in Worcester, Western Cape, and looked at the 
safety and efficacy of the MVA85A vaccine in preventing TB infection and progression 
to disease in HIV-negative infants (Tameris, Hatherill et al. 2013). 
The Government of South Africa must continuously consider how best to invest the
resources available for health to address the quadruple burden of disease1. Over the
past 10 years, a number of new vaccines have been developed (e.g. pneumococcal,
rotavirus, and human papillomavirus).  The Ministry of Health needs to consider whether 
to introduce these new vaccines. One aspect of this decision making process is looking
at “cost-effectiveness” i.e. whether the resources that will be invested in delivering these
vaccines will produce sufficient health outcomes (e.g. prevent cases, deaths or disability) 
to justify the investment.
Objectives 
Our study compared the costs and health outcomes of two TB vaccine strategies:
i. BCG, given at birth, which is the current standard of care in South Africa; and
ii. BCG, given at birth, together with a booster vaccine (MVA85A) given at
4 months, which is the potentially new strategy.
The aim was to determine, which of these two strategies was more cost-effective from
the perspective of the South African Government.













To estimate the costs and health outcomes of the two strategies, a model was
developed using TreeAge® Pro 2012 software. The model followed a hypothetical
group of infants over a period of 10 years. The risks of being infected with TB
(Kritzinger, den Boon et al. 2009, Middelkoop, Bekker et al. 2008, Shanaube,
Sismanidis et al. 2009, Wood, Liang et al. 2010, developing TB disease (Provincial 
Government Western Cape Department of Health 2012), dying from TB (Statistics 
South Africa 2012), and dying from causes other than TB (World Health Organization
Global Health Observatory (GHO) 2012) was taken from South African data; as was the
data on the cost of BCG vaccination and the cost of diagnosing and treating three types
of childhood TB (pulmonary, miliary, and meningeal) (Mandalakas, Hesseling et al.
2013). The efficacy (how well the vaccine works) of the MVA85A vaccine was taken
from the published trial data (Tameris, Hatherill et al. 2013).
The model was used to calculate the absolute difference in the number of TB cases and
TB deaths between the two interventions i.e. BCG alone versus BCG + MVA85A. At
the end of the 10-year period the cumulative costs and outcomes of each intervention
were used to calculate the cost-effectiveness ratio (CER) (i.e. the cost per TB case
averted and the cost per TB death averted) for each intervention. These two cost-
effectiveness ratios were compared using an incremental cost-effectiveness ratio
(ICER), which represent the additional cost per additional benefit received.
Results 
Unfortunately, the MVA85A trial data only showed an efficacy of 17.3% in preventing TB 
in HIV-negative infants when given as a booster to the existing BCG vaccines.  This has 
heavily impacted on the results of this cost-effectiveness study. 
The results indicate that the MVA85A strategy is both more costly and more effective – 
there are fewer TB cases and deaths from TB – than BCG alone.  The Government 
would need to spend an additional USD 1,105 for every additional TB case averted and 











Table 1: Cost-effectiveness of adding the MVA85A vaccine to the BCG vaccine 









Number of TB 
deaths 
ICER 








BCG alone 84.17 0.09101 0.0003501817 
plus MVA85A 98.23 0.07828 0.0003006626 1,105 284,017 
Undiscounted 
BCG alone 97.65 0.10627 0.0004174069 
plus MVA85A 109.80 0.09138 0.0003583168 816 205,603 
South Africa does not have a defined acceptability threshold. If we consider the
recommendations made by the Commission on Macroeconomics and Health, then at
South Africa’s GDP per capita of USD 8,070, the vaccine would be considered highly
cost-effective in terms of TB cases averted.
The sensitivity analyses suggest that the results are sensitive to the price at which the
vaccine will be made available, the annual risk of being infected (ARI) with TB, and the
efficacy of the vaccine. 
The threshold analysis shows that, if the efficacy of the MVA85A vaccine was 41.361% 
(instead of the current efficacy of 17.3%), the two strategies would have the same cost 
but more cases of TB and more deaths from TB would be prevented by adding the
MVA85A vaccine to the BCG vaccine. In this case, Government should consider the
MVA85A strategy.
Policy Recommendations 
This cost-effectiveness study shows that adding the MVA85A vaccine to the BCG 
vaccine is both more costly and more effective in preventing TB disease and deaths 
from TB than using BCG alone.  However, the clinical study shows that, in HIV-negative 











vaccine.  Therefore, adding MVA85A as a booster to BCG against infant and childhood
TB is not cost-effective, and is not a good use of Government’s limited resources.
Furthermore, the study indicates that, a new TB vaccine with an efficacy of, at least,
41.361% and provided at the same price as the MVA85A vaccine, would have the same 
cost to Government as using the BCG vaccine, but prevent more cases of childhood TB 
and more deaths from TB.  In this case, the Government should consider investing in
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